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ABSTRACT 
 
The rapid surge in drug-resistant bacterial infections has now become one of the 
primary public health crises of the 21st century. In a world without effective antibiotics, 
modern surgical and medical procedures will become too dangerous or impossible due to 
the threat of untreatable bacterial infections. As discussed in Chapter 1, the emergence of 
antibiotic resistant bacteria threatens to render a majority of the current antimicrobial 
therapeutics ineffective. Every year in the United States alone, over two million people 
are afflicted with bacterial infections that are resistant to FDA-approved antibiotics. 
According to the CDC, over 20,000 of those patients died as a result of drug-resistant 
Gram-positive bacterial infections, such as Streptococcus pneumoniae (S. pneumoniae), 
Enterococcus faecium (E. faecium), and Staphylococcus aureus (S. aureus). Equally 
alarming is the emergence of multidrug Gram-negative pathogenic bacteria, including 
strains that are resistant to all currently available antibiotics. As the number of efficacious 
antibiotics continues to rapidly dwindle without replenishment, the possibility of entering 
a post-antibiotic era can become a reality. Discovery and development of drug leads 
against the most serious pathogenic bacteria is desperately needed to reinvigorate the 
antibiotic pipeline and reverse this alarming trend.  
This thesis will discuss the design of two immunotherapy strategies that target 
bacterial cells for destruction via surface modeling conjugates that specifically home to 
bacterial cell surfaces. The Pires lab has pioneered the field of bacterial immunotherapy 
for the eradication of Gram-positive bacteria. In Chapter 2, we will highlight previous 
reports of facile bacterial surface modulation strategies that act to stimulate or attenuate 
the host immune system. We have extended our techniques of bacterial surface 
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remodeling with the goal of reactivating the host immune system to seek out and directly 
clear pathogenic bacteria. In Chapter 3, we set out to leverage the surface-homing 
properties of vancomycin to specifically tag the surface of Gram-positive Staphylococcus 
aureus with immune cell attractants.   Vancomycin was conjugated to a small molecule 
hapten, known to effectively recruit endogenous antibodies. In combination with sortase 
A-mediated surface remodeling, which are house-keeping enzymes that catalyze selective 
and covalent modification of bacterial cell walls, we successfully demonstrated the 
tagging and recruitment of endogenous anti-DNP antibodies to the surface of S. aureus. 
We also showed, for the first time, in vivo selective targeting of S. aureus in live C. 
elegans, a widely used model host to understand bacterial pathogenesis and host-
pathogen interactions. Together, our results pave the way for a narrow-spectrum strategy 
for the destruction of bacterial infections caused by S. aureus (drug-sensitive and -
resistant) through bacterial immunotherapy. 
Chapter 4 will discuss our goal is to eradicate Gram-negative superbugs by 
targeting problematic pathogenic bacteria for destruction by the host immune system. In 
this second major strategy, we report the design and development of a series of 
polymyxin B conjugates (a last resort antibiotic against Gram-negative pathogens), which 
are, to our knowledge, the first class of synthetic molecules that remodel Gram-negative 
bacterial cell surfaces with immune cell attractants. Given the inherent antimicrobial 
activity of polymyxin B, we designed agents to display dual activities against bacteria 
(membrane-disruption and immune activation). By leveraging the power of the immune 
system in clearing pathogens, this new class of molecules was shown to uniquely target 
Gram-negative bacteria and, additionally, potentiate existing FDA-approved antibiotics. 
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Additionally, in this study, the recruitment of antibodies from pooled human serum is 
shown, thus validating the biological relevance of this immunotherapy. We hope to 
establish this approach as a potential treatment option and further refine this methodology 
to address the clinical challenge of Gram-negative bacterial pathogens.  
The last chapter of this thesis focuses on the development of a facile assay to 
monitor the activity and inhibition of two isoforms of the Peptidylarginine deiminases 
(PAD) family: PAD2 and PAD4. PADs are post-translational modifiers that catalyze the 
calcium-dependent conversion of arginine residues to unnatural citrulline residues in a 
protein substrate. The full extent of the role PADs play in normal physiology and 
diseased states is not yet fully understood. PADs have important roles in the formation of 
Neutrophil Extracellular Traps (NETs), which was a recently discovered response of the 
immune system against bacterial pathogens. NETs are biomolecules that encase invading 
pathogens, which immobilize them to assist in their clearance by the human immune 
system. We report on a new, fluorescence-based assay, which is readily performed under 
ambient conditions and is compatible with high-throughput screening platforms. 
Furthermore, through a collaboration with Penn State Hershey Medical Center, we 
utilized the assay in a high-throughput screen for potential PAD4 inhibitors.  
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Chapter 1 
 Pathogenic Bacteria 
1.1 Microbes  
The sheer number of the projected bacterial species on Earth can be difficult to grasp 
– with a total number well into the millions of individual species.1 Bacteria are single-cell 
microorganisms, a few micrometers in length, that normally exist together and are 
characterized by a lack of a nucleus structure and membrane-bound organelles.2 Due to 
their high adaptability to different environments, bacteria are found in even the harshest 
conditions on Earth. In fact, it has been reported that much of Earth’s biomass is 
composed primarily of bacteria.3 The ability of bacteria to survive, adapt, and thrive in 
unusual environments is primarily driven by three features: a relatively high mutation 
rate, their small sizes, and a rapid binary cell division rate. The mutation rate for bacteria 
has been estimate at 0.003 mutations per genome per cell.4 . This is sharp contrast to 
humans, which have mutation rates of ~2.5×10−8 per base per generation.5 The increased 
mutation rate naturally promotes the generation of mutants within a population that 
possess increased fitness. Their relatively small size functions to increase the population 
size in any niche they occupy, providing the opportunity for favorable mutations to 
accumulate. Finally, a large majority of bacteria divide rapidly – with some bacteria 
approaching doubling times in the matter of minutes. Together, these features are 
extremely favorable for the rapid evolution of offspring that can adapt to new and 
changing environments.  
Bacteria can also survive in less extreme environments such as soil, plants, ambient 
temperate water, and other modern-life surfaces. These are the same environments that 
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are occupied by humans. Not coincidently, humans and bacteria cross paths through our 
co-existence. But our relationship goes beyond a co- and -independent existence. In many 
ways, humans (similar to most complex life on Earth) have co-evolved with bacteria. The 
human body represents a unique and highly dynamic environment for trillions of bacterial 
cells living in and on an average person.6 The sheer number of bacterial cells means that 
these microbial communities have the potential to impact human health. Commensal 
bacteria are harbored in many different tissues through the body, which means the host 
immune system has to naturally adapt to these non-self cells. An imbalance of the host 
immune response can lead to a number of serious health diseases. For example, a highly 
attenuated response may lead to uncontrolled bacteria growth, while an overly aggressive 
response may lead to chronic or acute inflammation.  
Unlike the response to commensal bacteria, the human immune system must rapidly 
and efficiently attempt to eradicate pathogenic bacteria upon first exposure. In most 
instances, this is exactly what happens. The human immune system (both the innate and 
the adaptive arms) has evolved diverse and incredibly precise modes of detecting, 
responding, and clearing pathogens. Likewise, pathogens continue to evolve counter-
measures to the defense modalities employed by human immune systems. As such, there 
are instances when pathogenic bacteria successfully evade the host immune response. 
From the initial invader, an infection often ensues that requires the intervention of 
therapeutic agents, such as antibiotics. For example, the notorious Gram-positive 
bacteria, Staphylococcus aureus (S. aureus) is known to cause a high human burden 
resulting in infections in various tissues of the body. S. aureus has long been recognized 
as one of the most important bacteria that cause disease in humans and the incidence of 
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infections have dramatically increased in the last 50 years due to the emergence of drug-
resistant strains, the closed quarters associated with hospitals, and the high number of 
surgical procedures associated with modern medical interventions. Gaining access to the 
body through broken or punctured skin, S. aureus can cause serious infections such as 
bloodstream infections, pneumonia, or bone and joint infections. By readily multiplying 
and disrupting the normal function of healthy cells within a host organism, pathogenic 
bacteria will progress to a diseased state. If left untreated, the infection can rapidly 
escalate to become life-threatening. 
 
1.2 Antibiotic Treatment for Bacterial Infections 
Alexander Fleming’s 1928 discovery and 1942 clinical use of penicillin, started the 
Golden Age of antibiotics and marked the foundation for the treatment of infectious 
diseases.7 Within a decade after World War II, several additional classes of important 
antibiotics were making it to clinical settings for the treatment of infections caused by all 
major types of bacteria. A majority of antibiotics being discovered during this era and 
since are natural products – molecules synthesized and extracted from living organisms. 
In fact, most of these antibiotics were produced by bacteria in an effort to reduce 
competing bacterial populations with the goal of gaining a competitive advantage in a 
world of limited resources. In a way, modern human medicine has been beneficiaries of 
the constant battle for space and resources on the part of environmental microbes. Over 
the course of millions of years, microbes have evolved extremely potent and small 
molecule drugs that target neighboring bacterial populations. As we harnessed these 
agents for our own use, it is clear today that these small antimicrobial molecules 
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revolutionized the field of modern medicine. For several decades following the discovery 
of antibiotics, deaths associated with bacterial infections plummeted. Most modern 
households were well stocked with an arsenal of potent antibiotics in a myriad of 
products including soaps, detergents, cosmetic creams, toothpaste, and primary care 
products. Most important, the advent of invasive surgeries and cancer therapies 
previously deemed too precarious due to risk of infection became routine procedures in 
the medical setting and led to a dramatic increase in the quality of life. It is no 
coincidence that since the introduction of antibiotics into the clinics, the average life 
expectancy has increased by nearly three decades.8 
Most antibiotics target specific biological processes in bacteria. If the disruption to 
this process is severe enough, the agent will result in bacterial death. Within the naturally 
existing bacterial warfare, a series of antibiotics have been previously cataloged against a 
large majority of pathogenic bacteria that infect human beings.9 Effective antibiotics 
work by inhibiting vital cellular processes that bacteria require in order to survive, such 
as DNA replication, protein synthesis, and cell wall biosynthesis. Of these classes, 
inhibitors against cell wall biosynthesis represent the largest and most widely subscribed 
class of antibiotics owning to their lack of human counterparts. Eukaryotic cells do not 
possess a structural unit similar to cell walls, opening the door to several potential drug 
targets within the cell wall biosynthetic pathway.10   
Bacterial cell surfaces are heterogeneous mixtures comprised of lipids, proteins, and 
glycans. These complex molecular structures are responsible for providing bacteria with 
structural support and mediating interactions with its environment.11 Due to its role in 
maintaining bacterial viability, bacterial cell walls have been the primary target for some 
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of the first antibacterial agents discovered. Differences in architecture of these molecular 
structures also form the basis for the classification of bacteria into two main categories: 
Gram-positive and Gram-negative. Gram-positive bacteria contain a single lipid bilayer 
and a thick layer of peptidoglycan, comprised of multiple layers of glycan strands that are 
cross-linked by oligopeptides.12  The Gram-positive designation refers to the ability of 
these cells to retain the Gram stain via the peptidoglycan scaffold, which becomes readily 
visible under light microscopy. Conversely, bacteria that are unable to retain the Gram 
stain are Gram-negative bacteria and are referred to as diderms, containing two lipid 
bilayers separated by a thin layer of peptidoglycan13 (Figure 1.1). In other words, the 
additional outer membrane found in Gram-negative organisms function to reduce 
permeation and accumulation of the Gram stain. Consistently, Gram-negative bacterial 
species are more difficult to kill due to the protective nature of the outer lipid membrane, 
which effectively prevent the facile passage of most antibiotics.  
There are two major categories that separate the mechanisms of antibiotics, namely 
bactericidal and bacteriostatic agents. A bactericidal antibiotic interferes with crucial 
processes, leading to effective cell death. A large number of FDA-approved antibiotics 
that act as bactericides happen to target the peptidoglycan building blocks necessary for 
cell wall synthesis (Table 1.1).14  Currently, β-lactam antibiotics represent more than half 
of the antibiotics that are used in clinical settings. 
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β-lactam antibiotics effectively block cell wall crosslinking by covalently modifying 
a critical serine residue at the active side of cell-anchored transpeptidases, which reduces 
peptidoglycan integrity and causes cell death. Glycopeptides, such as vancomycin, arrest 
peptidoglycan synthesis by binding to and sequestering lipid II precursor molecules. 
Lipid II molecules are responsible for translocating monomeric peptidoglycan building 
blocks from the cytosolic space, where it is biosynthesized, to the mature peptidoglycan 
scaffold. By blocking the delivery of monomeric peptidoglycan building blocks from the 
cytosol to the growing scaffold on the bacterial cell surface, cell wall biosynthesis comes 
to a halt. Antibiotics targeting bacterial DNA replication and repair enzymes also fall in 
Figure 1.1 Bacterial Classification. Cell wall composition of the 
two main types of bacteria, Gram-negative and Gram-positive. 
Gram-negative bacteria exhibit a thin peptidoglycan layer and an 
outer lipid membrane whereas Gram-positive bacteria contain a thick 
layer of peptidolgycan and lack an outer membrane. 
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the bactericidal category. These agents operate by inhibiting enzymes, such as 
topoisomerases and DNA gyrase, which are vital processes for the maintenance and 
growth of bacterial cells. Fluoroquinolones are considered a broad-spectrum agents that 
are effective against both Gram-negative and -positive bacteria, antibiotic within this 
class. 
Bacteriostatic antibiotics are different from bactericidal antibiotics in that these agents 
shut down active bacterial growth but do not cause cell death. Antibiotics in this class 
take advantage of non-eukaryotic structural characteristics of ribosomal subunits and 
other factors involved with initiation, elongation, and termination in bacterial protein 
synthesis. FDA-approved antibiotics in this class include tetracyclines and 
aminoglycosides, which target different parts of the ribosome machinery to effectively 
terminate protein synthesis. For example, clindamycin is commonly prescribed for the 
treatment of S. aureus.  
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For many decades, the number of new antibiotics introduced into the clinics easily 
outpaced the emergence of resistant strains. Although the discovery and use of antibiotics 
was thought to signal the end of infectious diseases, the overuse and misuse of antibiotics 
has led to the emergence of bacterial strains that are resistant to several if not all 
approved antibiotics.  
 
Classification Antibiotic Example 
Bacteriostatic/ 
Bactericidal Mechanism of Action 
Target 
Bacteria 
β-Lactam 
Penicillin / 
Amoxicillin  
Bactericidal 
 
Inhibit cell wall synthesis  
 
Gram-
positive 
 
Glycopeptides Vancomycin 
Lincosamides Clindamycin Bacteriostatic Inhibit protein synthesis 
Sulfonamides 
Trimethoprim-
Sulfamethoxazole 
Bacteriostatic 
Inhibit nucleic acid synthesis 
 
Broad 
Spectrum 
 
Tetracyclines Doxycyclin Inhibit protein synthesis 
Fluroquinolones 
Ciprofloxacin / 
Levofloxaxin 
Bactericidal Inhibit DNA replication 
Cephalosporins Cefclidin (4th generation)  Bactericidal 
 
Inhibit cell wall synthesis 
Carbapenems Miropenam 
Aminoglycosides Streptomycin 
Bactericidal 
Inhibit protein synthesis 
Gram-
negative 
 
Monobactams Aztreonam Inhibit cell wall synthesis 
Polypeptides Polymyxin B / Colistin 
Disrupt outer membrane 
integrity 
Table 1.1 Common Antibiotics Prescribed for Bacterial Infections.  
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1.3 Mechanisms of Antibiotic Resistance in Bacteria 
 
Over 60 years of antibiotic use has led to a precarious new reality – a scenario in 
which pathogenic bacteria have taken the upper hand and our ability to fight bacterial 
infections has been heavily eroded. This new era was brought on by decades of 
antibiotic use and misuse. Yet, in many ways, resistance to antibiotics is nothing new 
nd not purely a human-mediated effect. Given the source of most antibiotics in use 
today – natural products from bacteria – bacteria have been evolving mechanisms of 
resistance slowly over millions of years.15 Bacteria have been fighting off natural 
“predators” since their first widespread existence on Earth. The rapid growth rates 
and promiscuous gene swapping by bacteria form the basis for rapid evolution and 
propagation of favorable phenotypes.16 In combination with the exposure to 
antibiotics, there is a clear and strong selective pressure on the heterogeneous 
population of bacteria, leading to the rapid elimination of the susceptible members 
and leaving the few resistant members to replicate and flourish.17  
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While natural evolution outside of human hosts has previously, and will continue 
to, shape the resistance profile of bacteria, human beings have played a major role in 
accelerating this process. A steady increase in frequency of drug resistant bacterial strains 
have been reported since the beginning of the Golden Era for virtually all major classes 
of antibiotics. The overuse and misuse of antibiotics are two major reasons for the 
Figure 1.2 Bacterial Antibiotic Resistance Mechanisms. Bacterial have devised 
several methods of antibiotic resistance. Decreased uptake – poor antibiotic 
permeability through the cell wall will make some antibiotics ineffective. Target 
alternations – bacteria can modify the target to dodge the antibiotic yet remain 
safe for the bacteria. Alternative enzyme – Bacteria can utilize a different enzyme 
for cellular processes which is not affected by the antibiotic. Inactivating enzymes 
- bacteria have developed mechanisms, such as enzyme mediated antibiotic 
hydrolysis, to alter the structure of the antibiotic and destroy the effects of the 
therapeutic. Efflux pumps – actively transport therapeutics out of the cell. 
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emergence of drug resistant strains. Overuse of antibiotics typically refers to the use in 
farm animals, which can account for a large percentage of antibiotics produced on a 
yearly basis*. Misuse of antibiotics mostly refers to the prescription of antibiotics for 
viral infections and incomplete use of the entire course of antibiotics that are prescribed. 
When administration of a course of antibiotics is not followed according to 
recommendations, it can lead to incomplete clearance of pathogens from the system. The 
remaining bacteria typically have acquired mutations that can be passed on to future 
generations. Moreover, the genetic information that encoded the superior phenotype can 
be additionally passed onto other bacteria as it is spread back out to the natural 
environment. Drug resistance is a phenomenon that is observed in virtually all known 
bacteria that can occur in an inter- and intra-species modalities. A single mode of drug 
evasion can be enough to endow bacteria with a drug-resistant phenotype. Yet, it is now 
clear that bacteria can acquire several genes that confer competitive advantages against 
antibiotics, making these strains exceedingly dangerous.18 These bacteria are known as 
multidrug-resistant (MDR), extremely drug-resistant (XDR) or pandrug-resistant (PDR) 
bacteria.19 These are all designations that refer to bacteria that can cause infections that 
are mostly untreatable.  
Bacteria possess diverse and incredibly efficient methods to avoid the toxic 
actions of antibiotics. Drug modification or degradation, efflux pumps, decreased 
permeation of drugs, and drug target alteration are the most common mechanism used by 
bacteria to circumvent antibiotics (Figure 1.2).20, 16, 21 An effective and widely employed 
resistance mechanism used by bacteria involves the reduction in access of antibiotic to its 
molecular target, which can result in insufficient concentration to impart its intended 
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biological response (Figure 1.2). This can be an inherent resistance mechanism as in the 
case for vancomycin against Gram-negative pathogens. Vancomycin associates tightly 
with the peptidoglycan precursor molecules, lipid II. Pools of lipid II are found primarily 
on the cytoplasmic membrane of bacteria around the sites of cell division and growth. 
Both Gram-positive and Gram-negative bacteria possess peptidoglycan, and, in theory, 
both should be equally sensitive to the actions of vancomycin. However, the outer 
membrane layer found on the surface of Gram-negative bacteria severely restricts 
accumulation of vancomycin within the periplasmic space (site of lipid II in Gram-
negative bacteria), thus preventing access to its molecular target. Vancomycin cannot 
overcome this limitation, and, therefore, is only effective as a stand-alone antibiotic 
against Gram-positive bacterial infections.  
Another widely observed mechanism used by bacteria use to circumvent the 
actions of antibiotics occurs via the structural alteration of the molecular target of that 
particular drug (Figure 1.2). A mutation at the genetic levels results in a protein target 
with an altered primary sequence (a replacement of an amino acid). Protein changes that 
result in lower binding to the antibiotic will give that particular bacterial cell a selective 
advantage. Alternatively, a similar drug-resistant phenotype can be selected whereby the 
primary sequence of the target protein remains unchanged. For example, ribosomal 
protection proteins protect ribosomes from the action of antibiotics by directly interacting 
with the ribosome and changing their shape or conformation. The change in the ribosome 
shape prevents an antibiotic from binding and interfering with protein synthesis.22  
Drug modification or degradation by an inactivating enzyme is another prevalent, 
and highly effective, mechanism of resistance against β-lactam antibiotics (Figure 1.2). β-
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lactam antibiotics work by structurally mimicking the dipeptide D-Alanyl-D-Alanine, 
which the terminal group found on the stem peptide of bacterial peptidoglycan, and 
effectively inactivating Penicillin Binding Proteins (PBPs). PBPs are responsible for 
crosslinking adjacent stem peptides within the peptidoglycan scaffold, thus increasing the 
strength and stiffness of this critical cellular matrix. This crosslinking step is crucial to 
the viability of bacterial cells and its disruption is lethal to the cells. The crosslinking 
reaction carried out by PBPs is initiated at the D-Alanyl-D-Alanine terminal end of the 
peptidoglycan. The strained β-lactam bond and the proper mimicry of D-Alanyl-D-
Alanine by these antibiotics results in a covalent capture of the active site of PBPs. 
Consequently, PBPs modified with β-lactam cease to crosslink the peptidoglycan scaffold 
and cell death follows.  
Bacteria resistant to β-lactam antibiotics respond to the presence of these drugs by 
releasing high levels of β-lactamase proteins into the surrounding media. β-lactamases 
enzymatically hydrolyze the β-lactam bond, which renders these drugs poor mimics of D-
Alanyl-D-Alanine and  unable to covalently capture PBPs.23 The use of β-lactamase 
inhibitors in combination with a β-lactam antibiotic has previously proven effective at 
treating these β-lactam-resistant bacteria.24 This combination is commonly prescribed as 
augmentin, which is composed of clavulanic acid, a β-lactamase inhibitor, and 
amoxicillin. Not surprisingly, it was not long after clavulanic acid was first used in clinics 
before bacteria have found a way around this drug combination as well.25 The short 
amount of time needed for bacteria to find a way around this combination of drugs 
highlight the ability of bacteria to gain resistance to antibiotics. In this particular instance, 
bacteria that survived augmentin started to shift the crosslinking function away from 
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PBPs to other enzymes in order to crosslink their cell walls. L,D-transpeptidases, which 
are normally used to perform a separate task in bacterial cells and are structurally distinct 
from PBPs, are inherently insensitive to β-lactam agents.26, 27, 28, 29, 30 Therefore, cells that 
transferred the crosslinking function to L,D-transpeptidases were able to grown and 
proliferate in the presence of high levels of most β-lactam antibiotics. 
Likewise, bacteria have developed additional mechanisms to use alternative 
enzymes to carry out cellular processes. As a resident of the human skin, nails, and nares, 
S. aureus has the unique ability to penetrate deeper layers of host barriers. S. aureus have 
evolved three unique mechanisms to avoid the actions of two distinct classes of 
antibiotics. Methicillin resistant S. aureus (MRSA) shift the crosslinking functions 
necessary for cell wall growth and division to avoid inactivation by β-lactam antibiotics. 
Strains of MRSA express high levels of a PBP variant, PBP2a, that has inherently low 
affinity for β-lactam antibiotics *. This unusual PBP serves as a fully functional enzyme 
within the peptidoglycan biosynthetic pathway. The slower acylation of the active site 
serine in PBP2a forms the basis for a drug-resistant phenotype. Two additional modes of 
drug resistance against vancomycin in S. aureus exemplify the plasticity in bacterial cells 
in their ability to alter structural and biochemical pathways to endow new and favorable 
phenotypes. In the first mode, S. aureus avoid the actions of vancomycin by increasing 
the levels of D-Alanyl-D-Alanine on the peptidoglycan structure as a way of capturing 
vancomycin molecules away from the lipid II pool near the cell membrane.31 The simple 
expansion in the valency of dipeptides present in the mature peptidoglycan scaffold can 
be enough to reduce the susceptibility of vancomycin to disrupt new cell wall growth. In 
the second mode, S. aureus cells perform a wholesale alteration of their peptidoglycan 
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structure to include a terminal D-Lactic acid (D-Lac) in place of the terminal D-Alanine 
(D-Ala) residue within the stem peptide of the peptidoglycan.32 Although structurally 
subtle, the primary sequence change from D-Alanine to D-Lactic acid eliminates a single 
hydrogen bond and, consequently, results in 1000-fold weaker binding affinity to 
vancomycin.33 Exposure to vancomycin triggers a shift in cell wall biosynthesis towards 
the intracellular production of D-Lac and D-Lac terminated building blocks. Pyruvate is 
converted to D-Lac and ligated onto D-Ala by the ligases to afford D-Ala-D-Lac. This unit 
is joined onto a tripeptide by MurF to yield the full PG pentadepsipeptide precursor, 
which is subsequently loaded onto the lipid carrier. Yet, production of D-Ala-D-Lac alone 
is insufficient to impart vancomycin resistance due to the continued cytosolic production 
of D-Ala-D-Ala. If available, D-Ala-D-Ala will also enter the PG biosynthetic pathway 
and generate vancomycin-susceptible Lipid II molecules. To ensure that primarily D-Lac 
terminated Lipid II molecules are assembled, a carboxypeptidase (vanX) is also encoded 
on the resistance plasmid. This enzyme is tasked with the proteolysis of the dipeptide D-
Ala-D-Ala, thus greatly reducing the production of D-Ala terminated Lipid II molecules. 
Through the concerted actions of these enzymes, vancomycin resistant S. aureus cells 
continue to grow and proliferate in the presence of high concentrations of vancomycin. 
Finally, it is now well established that the overexpression of membrane proteins 
that act as efflux pumps are, at least partly, responsible for the emergence of multi-drug-
resistant bacteria.34 Efflux pumps export antibiotics (along with many other small 
molecules) from the inside the target bacterial cells out to the extracellular space. In 
effect, drugs cannot accumulate to sufficiently high levels to impart their biological 
activity. A feature that makes these efflux pumps extremely problematic for drug design 
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and discovery is that they tend to exhibit a low degree of specificity therefore they 
recognize and pump out a myriad of structurally unrelated antibiotics with diverse 
mechanisms of action. A common and problematic opportunistic pathogen, Pseudomonas 
aeruginosa, exhibits low susceptibility to antibiotic treatment due to the action of 
multidrug efflux pumps and low permeability of the antibiotics across bacterial outer 
membrane.35 Recent reports have shown that the combination of phenylarginine-β-
naphthylamide, an efflux pump inhibitor, and cefepime (a β-lactam antibiotic), re-
sensitized cefepime resistant Pseudomonas aeruginosa to the drug.36 These promising 
early results demonstrate the possibility of targeting the inactivation of drug efflux pumps 
with the goal of potentiating known antibiotics and improving the activity of drugs 
currently in the pipeline. 
Together, the diversity of mechanisms and the speed of resistance acquisition 
signify that our current stock of antibiotics will have a fairly limited utility lifespan. The 
continued use and misuse of antibiotics will propel us into a post-antibiotic era unless 
there is a re-dedication of effort and resources towards the discovery of new antibiotics. 
Today, drug resistant pathogenic bacteria are already responsible for thousands of deaths 
and billions of additional health care costs each year. Although novel antibiotics are 
urgently needed, no new class of antibiotics has been discovered since the 1980s (Figure 
1.3). This has become a serious problem in hospitals as bacterial resistant infections 
continue to be on the rise despite the practice of standard precautions.   
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1.4 Treatment of Antibiotic Resistant Bacterial Infections  
With the increasing incidences of drug resistant bacterial infections, last resort 
antibiotics, such as vancomycin and colistin, have now become front-line therapeutics. 
Even more troubling is the presence of vancomycin-resistant bacterial strains37 and 
colistin-resistant Escherichia coli.38,39 The widespread dissemination of these pathogens 
may rapidly increase the cases of untreatable infections.40, 16 If current trends continue, 
modern healthcare standards will be in jeopardy. Recent estimates project that by 2050 
more people will die from antimicrobial resistant infections than from all forms of cancer 
combined.41 
Figure 1.3 Classes of Antibiotics. Chart highlighting the lack of new 
classes of antibiotics in the past 3 decades (source: Pew Institute). 
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While the lack of new antibiotics being introduced into clinical settings needs to be 
addressed from a medical, government, and training level, there are a number of 
promising avenues being currently pursued. One example of a class of potential 
antibiotics that are effective against antibiotic-resistant bacteria focuses on derivatization 
of current antibiotics. For example, the Boger group at Scripps Research Institute has a 
long history of designing and synthesizing vancomycin derivatives that have improved 
activities compared to the parent drug.42, 43 In order to try and regain the lost binding 
affinity of vancomycin against D-Lac displaying drug resistant strains, a series of 
vancomycin analogues was synthesized with modifications focused on improving the 
binding to D-Ala-D-Lac strands. Their successful vancomycin displayed a 40-fold 
increase in affinity for D-Ala-D-Lac. Most importantly, the derivative also was effective 
against vancomycin-resistant Enterococcus faecalis (VRE) (MIC = 31 µg/mL).43 
 Some potential methods to expand the antibacterial therapy repertoire target non-
direct killing modalities. A promising strategy is aimed at inhibiting the ability of bacteria 
to communicate with one another.44 Bacteria use small diffusible molecules to distribute 
information about population density in a process termed quorum sensing. Quorum 
sensing has been proposed to play a role in bacterial pathogenicity. Communication 
between pathogenic bacteria can potentially provide a mechanism to minimize host 
immune responses by delaying the production of tissue-damaging virulence factors until 
sufficient bacteria have accumulated and the cells, in sync, are prepared to overwhelm 
host defense mechanisms to establish a robust infection. Therefore, the inhibition of these 
molecules may result in decreased colonization and virulence.  
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Although not approved in the United States, bacteriophage therapy has had 
remarkable success in Europe for antibiotic-resistant bacterial infections. Bacteriophages, 
commonly called phages, are viruses that infect bacteria but not mammalian cells.45 After 
penetrating the bacterial surface, phages will hijack bacterial DNA, and then replicate 
themselves within the bacteria until the cell bursts – depending on the lifecycle of the 
bacteriophage. Cocktails of phage viruses matched against pathogenic bacteria of interest 
can effectively cure a bacterial infection in the human body with remarkable accuracy, 
taking out only the infiltrators.46  
Recently, the World Health Organization (WHO) assembled a list of pathogens 
desperately needing new therapies. At the top of the list are three drug-resistant Gram-
negative bacteria followed by vancomycin-resistant E. faecium and MRSA (Figure 1.4). 
This thesis presents a novel non-direct killing method of combatting pathogenic bacteria 
by use of bacterial immunotherapy, specifically targeting MRSA and Gram-negative 
pathogenic bacteria.  
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Figure 1.4 Pathogen Priority Level. The World Health 
Organization’s list of top priority pathogens desperately needing 
new antibiotics. 
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Chapter 2 
Bacterial Immunotherapy 
2.1 Introduction 
The threat of antibiotic-resistant strains urgently calls for the development of novel 
multi-pronged approaches, including improved stewardship of known antibiotics, in the 
development of effective vaccines or alternative strategies to treat bacterial infections. 
Agents that circumvent antibiotic resistance by targeting pathogens for host immune 
clearance have the potential to selectively stimulate protective immune responses as a 
treatment option for bacterial infections.1  
Of the many systems in the body, the human immune system is one of the most 
important. Composed of a myriad of cellular mechanisms this complex network works as 
a defensive biological response to dangerous pathogens. The immune system recognizes 
potentially harmful substances, such as viruses, bacteria, and fungi, and sequentially acts 
to neutralize these foreign invaders. An effective immune system will successfully clear 
infectious material while sparing healthy human cells. Yet, the immune system’s ability 
to neutralize destructive offenders it not limited to foreign organisms. It can also offer 
support in the clearance of distorted cells, such as cancerous cells. In this case, 
elimination is carried out by tumor-specific T cells, immune cells developed specifically 
to target and attack cancer cells. However, cancerous cells have done well at evading the 
host immune system.2 To achieve evasion, tumors use powerful adaptations to disrupt 
equilibrium and suppress the immune system, such as manipulation of checkpoint 
pathways.3 When this manipulation occurs, checkpoint pathways like CTLA-4 or PD-1 
are activated to release a negative signal down-regulating the immune system and 
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promoting self-tolerance by suppressing T cell inflammatory activity. This host immune 
evasion upsets the delicate balance of the immune response, potentially leading to dire 
repercussions and serious health implications. Similarly, pathogenic bacteria have also 
evolved to thwart clearance by the immune system. When evasion is extremely 
successful, further medical intervention is required, in the means of antibiotic delivery or 
surgery to remove the untreatable infection.  
The external surface of bacterial pathogens presents many diverse antigenic targets 
for the host immune system. As the central interface between host and pathogen, 
recognition of the exposed surface by the immune systems provides the host a key 
signature to initiate microbial clearance. It also affords the pathogen significant 
opportunity to present mimics of host immune modulators, alter host immune responses, 
express adhesins or receptor ligands to anchor the pathogen to host surfaces, and to 
present invasins or fusion proteins to mediate uptake into host cells.4, 5  
A major difficulty for bacterial pathogens is hiding this complex surface of proteins 
and carbohydrates from immune surveillance and TLR recognition yet exposing key 
molecules, such as adhesins and invasins. A common mechanism of masking bacterial 
surfaces is to express a carbohydrate capsule. This mechanism is used by most 
extracellular bacterial pathogens that circulate systemically within the body. For example, 
Streptococcus pneumoniae relies extensively on its capsule to prevent antibody and 
complement deposition on its surface, thereby avoiding opsonization and phagocytic 
clearance.6 
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Bacterial pathogens, especially Gram-negative pathogens, have developed secretion 
systems to export virulence factors across the bacterial membranes and either into the 
supernatant or directly into host cells. Secretion of virulence factors such as toxins and 
immune modulators is a major use of these secretion systems.7, 8 In Gram negative 
pathogens, both type III secretion systems (T3SS) and type IV secretion systems (T4SS) 
can insert various molecules directly into host cells, including toxins, mechanisms to 
paralyze phagocytosis, and many diverse effectors that alter immune functions to enhance 
immune evasion.  
 
2.2 Bacteria and the Human Host 
In the last few years, we have learned that humans share a complicated and intricate 
co-existence with bacteria living in and on our bodies. The sheer number of bacteria cells 
means that these microbial communities have the potential to impact human health. There 
exist two types of bacteria, probiotic and pathogenic bacteria. Probiotics, like 
Lactobacillus, are beneficial to our health, primarily aiding in a healthy digestive 
system.9 Unlike the response to commensal bacteria, the human immune system must 
rapidly and efficiently attempt to eradicate pathogenic bacteria upon exposure. An 
imbalance of the host immune response can lead to a number of serious health 
implications. An overly aggressive response may lead to chronic or acute inflammation, 
whereas a highly attenuated response may lead to uncontrolled bacteria growth.  
In the case of the latter, uncontrolled bacteria growth may also be due to evasion of 
the host immune system. As discussed in the previous section, bacterial pathogens have 
mechanisms in place in order to thwart clearance by the immune system. Therefore, in 
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response to threat, researchers have developed bacterial immunotherapies that operate by 
provoking a selective native immune response against evading pathogenic bacteria. 
Treatment of microbial infections using this novel methodology possesses two main 
benefits. First, the immune system has evolved to combat pathogenic bacteria. In fact, the 
innate human immune system is constantly detecting, engaging, and destroying 
pathogenic bacteria. As stated, it is only when the homeostatic balance between the host 
immune system and the pathogenic bacteria is compromised that a bacterial infection 
ensues. Secondly, by targeting the immune system of the host rather than the bacteria, the 
propensity for bacteria to evolve resistance via selective pressure is potentially reduced.1 
It is due to these two clear advantages that immunomodulatory drugs provide great 
potential as future antimicrobial therapeutics.  
 
2.3 Bacterial Immunotherapy 
Unfortunately, immuno-agents against bacterial infections have lagged behind 
traditional antibiotics despite the tremendous clinical success of immunotherapy in other 
disease areas.10  This is best illustrated in the field of cancer therapy. Cancer 
immunotherapeutics attack cancer cells by mounting or enhancing a selective immune 
response against the tumor cells. Immuno-oncology has resulted in unprecedented patient 
responses.10 Most significantly, more robust and sustained anti-cancer responses have 
been observed when compared to traditional cancer chemotherapeutics.11, 12, 13, 14 
Research groups have been working towards applying guiding principles from immuno-
oncology to design molecules that target pathogenic bacteria.15, 16, 17, 18 These strategies 
act to stimulate or attenuate the host immune system in a manner that is advantageous to 
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clearance of infection. By exploiting an emerging chemical understanding of complex 
biological systems, future efforts to rationally modulate human immunological functions 
have the potential to augment our ability to prevent, diagnose, and treat human disease. In 
this field, one of the most utilized methods of synthetically tagging bacteria for host 
immune clearance is the employment of antibody-recruiting small molecules (ARMs). 
 
2.3.1 Antibody-Recruiting Small Molecules (ARMs) for Bacteria Targeting 
To date, the display of antibody-recruiting small molecules (ARMs) on targets such 
as cancer cells, viruses, and bacteria has demonstrated high potential for stimulating the 
host immune system.19 Bacteria eradication by the immune system relies on surface 
“tagging” by antibodies. As such, synthetic ARMs are comprised of a target binding 
domain (surface of bacteria) and an antibody binding domain. Simultaneous association 
of ARMs with antibodies and surface-exposed targets results in the formation of ternary 
complexes, which can elicit antibody dependent immune effector responses. Two potent 
arms of the native immune system that can potentially lead to bacterial killing based on 
opsonization are antibody-dependent cellular cytotoxicity (ADCC) and complement-
dependent cytotoxicity (CDC) (Figure 2.1). 
In the latter, the recruitment of antibodies induces a complement-dependent cytotoxic 
(CDC) response, in which protein aggregates are formed in target membrane. This 
protein aggregate, known as the membrane attack complex (MAC), is responsible for 
lysing the target cell by forming pores in the membrane of the cell.20 This response does 
not rely on other immune cells, although the innate immune system is made up of 
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phagocytic cells (polymorphonuclear neutrophils, monocytes, macrophages), cells that 
release inflammatory mediator, and natural killer cells. This mechanism is generally 
thought to be utilized in the eradication of Gram-negative bacteria. 
The other mechanism, in which the immune system facilitates immune-mediated 
cytotoxicity, is through the recruitment of these aforementioned effector immune cells. In 
these types of immune responses, antibodies opsonizing the surface of target cells are 
recognized by effector immune cells. In the case of antibody-dependent cellular 
phagocytosis (ADCP), macrophages and neutrophils recognize opsonized bacterial 
surfaces and phagocytose target cells.21 Conversely, recognition of the antibody Fc region 
by natural killer cells results in immune cell release of proteins such as perforin, which 
subsequently destroy the target through lysis. This mechanism of immunity is antibody-
dependent cellular cytotoxicity (ADCC).22, 23 
 
34 
 
 
Immunotherapy with antibodies has taken the leading role in this development aided 
by the virtually unlimited supply of purified human mAbs, which are among the immune 
system’s most effective weapon against bacterial pathogens. Upon antigen labeling of 
target cell surfaces, these adaptive antibodies can bind and neutralize bacterial toxins, 
facilitate an immune response, and improve recognition and binding by phagocytic cells 
thereby increasing the phagocytic killing efficiency. In using this strategy for therapeutic 
purposes, antigens that bind endogenous antibodies are more appealing as they forgo the 
need for vaccination.  
Figure 2.1 Primary Modes of Pathogen Clearance based on Immunomodulators. 
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Few antigens are known to be recognized by endogenous antibodies. The first and 
most prominently utilized endogenous ARM is the carbohydrate galactosyl-(1-3) 
galactose (α-Gal) (Figure 2.2). With estimations of up to 8% of anti- α-Gal antibodies 
found circulating in the human blood stream, this trisaccharide epitope has produced 
robust immune responses used in developing cancer and HIV treatments.24, 25, 26, 
27Another carbohydrate-based antigen is L-rhamnose (Figure 2.2). Through extensive 
analysis of human sera samples derived from subjects of diverse ethnicities, ages, and 
gender, antibodies which bind L-rhamnose were found in greater concentrations in a 
higher proportion of people than the previously mentioned α-Gal.28 Recently L-rhamnose 
was used to label tumor cells and demonstrated its ability to inhibit tumor growth in 
vivo.29 Lastly, DNP is also known to recruit endogenous antibodies (Figure 2.2). 
Although antibodies for the previous two epitopes mentioned, have origins linked to 
bacteria, the presence of anti-DNP antibodies remains debated.30, 31 It is known that 1% 
of all antibodies circulating within the human blood stream will bind to DNP haptens.32, 
33, 34 Due to its chemical structure, constructing ARMs displaying the DNP epitope is 
facile in comparison to the previously mention carbohydrate antigens. The use of DNP 
conjugated ARMs has previously been used to elicit immunomodulation responses that 
have targeted human immunodeficiency virus (HIV), lung cancer, prostate cancer, and 
colon adenocarcinoma.35, 36, 37 
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A variety of ARM-based antibacterial strategies have been evaluated. The first 
example was reported by the Bednarski laboratory in 1992. They employed a rationally 
designed, bifunctional molecule capable of directing anti-avidin antibodies to E. coli.38, 39 
The target of interest was a mannose sugar receptor expressed on the pili of Escherichia 
coli (E.coli). Biotin was conjugated to the C-glycoside of mannose, a known ligand for 
bacterial mannose receptors, and this construct was shown to recruit anti-avidin IgG 
antibodies to the surface of E. coli in a manner dependent on the presence of conjugate, 
avidin, and antibodies. Furthermore, the researchers demonstrated that complexes 
between avidin, antibody, and ARM could mediate complement- and macrophage-
dependent cytotoxicity. 
More recently, in 2003 and 2006, Whitesides and co-workers developed ARMs that 
target pathogenic bacteria by utilizing the potent antibiotic vancomycin.40, 41 Constructing 
vancomycin- fluorescein polyvalent polymers allowed for the targeting of the surface of 
several Gram-positive bacteria, including S. aureus, S. epidermidis, and S. pneumoniae). 
Figure 2.2 Chemical Structures of Antigens Capable of Recruiting Endogenous 
Antibodies. Galactosyl-(1-3) galactose, rhamnose, and dinitrophenyl are known to 
be epitopes or haptens for endogenous antibodies.  
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The polymeric vancomycin was used to target the site of new peptidoglycan and the 
fluorescein moiety promoted the recruitment of anti-fluorescein antibodies to the surface 
of various Gram-positive bacteria.  Using fluorescence microscopy and flow cytometry, 
the authors demonstrated that the antibody-recruiting polymer could mediate 
phagocytosis of opsonized bacteria in the presence of anti-fluorescein antibodies. 
Each of these previous studies demonstrates the feasibility of stimulating the host 
immune system as an effective strategy to thwart off pathogenic bacterial infections. 
However, these methods suffer drawbacks such as vaccination, low bioavailability, or 
indirect antigen cell surface labeling. The antigens utilized, biotin and fluorescein, would 
not be suitable for inducing an immune response without prior immunization. To mitigate 
this shortcoming, the hapten utilized should ideally recruit endogenous host antibodies to 
the bacterial surface.  
In 2014, the Pires laboratory pioneered the use of a direct targeting agent, where 
bacterial cell surfaces were selectively modified with antigens that recruit endogenous 
antibodies to eliminate the need for vaccination. Since then they have pioneered the field 
of bacteria immunotherapy utilizing haptens recognized by endogenous antibodies.15, 16, 17  
In their novel immunomodulation strategy, D-amino acid Antibody Recruitment Therapy 
(DART), they developed a series of D-amino acid derivatives that selectively modified 
bacterial cell surfaces with small molecule haptens. Synthetic D-amino acids were 
metabolically incorporated as cell wall building blocks, which led to cell surface 
presentation of unnatural sidechains modified with haptens. They showed that the 
presence of DNP-conjugated D-amino acids led to extensive peptidoglycan remodeling 
and triggered the recruitment of endogenous antibodies (existing antibodies in human 
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serum) and induced phagocytosis by macrophages. In a second generation form of 
DART, they showed the ability of PBP transpeptidases to incorporate D-amino acids 
possessing diverse C-terminus modifications. Through this study, it was observed that 
exogenous D-amino carboxamide variants are more readily incorporated into the 
peptidoglycan than the natural carboxylic acid containing D-amino acid substrate. They 
show that that DNP-conjugated D-amino carboxamides elicited a greater immune 
response in B. subtilis and E. faecalis.16 
Poignantly, the use of employing antibodies to treat infections has long ago been 
established. Using antibodies to treat infections became a reality in the late 1800’s when 
a German physiologist, Emil von Behring, developed serum therapies against diphtheria 
and tetanus.42 He found that he could transfer serum from infected horses to ill patients 
stricken with the disease. The antitoxins, as he coined them, from the horse serum 
targeted the disease in the patients and triggered a robust immune response. Stricken 
patients were healed and Von Behring later won the first Nobel Prize in medicine for 
employing antitoxins (antibodies, as we call them today) in 1901. Afterward, passive 
serum therapy was the preferred method in treating not only diphtheria and tetanus, but 
also scarlet fever and meningitis.43 As we are well aware of today, the use of the 
antiserum was particularly effective against pathogens, capable of evading the immune 
system. With the advent of antibiotic therapy, serum therapy faded into background. 
However, Von Behring’s discovery may be making its second debut as a life-saving 
remedy.   
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In this thesis, the development of an immunotherapy strategy to specifically target 
Staphylococcus aureus and the challenging Gram-negative pathogenic bacteria is 
discussed. By utilizing derivatives of antibiotics, which naturally home to the bacteria 
surface, bacterial cell surfaces were selectively modified with antigens that recruit 
endogenous antibodies. The antibody recruitment molecules were designed to afford high 
levels of bioavailability and selectively modulate bacterial surfaces in a direct manner to 
reduce off target immune responses effecting host cells. In Staphylococcus aureus, we 
report on the selective and covalent modification of the bacterial cell wall primed for the 
recruitment of endogenous antibodies. We also show, for the first time, in vivo selective 
targeting of S. aureus. In developing an immunotherapy strategy for Gram-negative 
bacteria, we describe the first class of synthetic molecules that remodel Gram-negative 
bacterial cell surfaces with immune cell attractants. The results of this thesis demonstrate 
a viable treatment option to address the clinical challenge of Staphylococcus aureus and 
Gram-negative bacterial pathogens.  
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Chapter 3 
Immuno-Targeting of Staphylococcus aureus via Sortase A-Mediated Incorporation 
of Vancomycin-Antigen Complexes 
3.1 ABSTRACT 
As the threat of methicillin-resistant Staphylococcus aureus continues to loom 
over the power of modern medicine, new methodologies to treat bacterial infections is of 
paramount importance. We set out to leverage the surface-homing properties of 
vancomycin to specifically tag the surface of Gram-positive pathogens with immune cell 
attractants. Vancomycin, which accumulates preferentially at the regions of cell 
division/growth (concentrated pools of Lipid II molecules), target a dipeptide motif found 
in the cell wall of bacteria. Additionally, previous research has shown that exogenous 
peptides can be covalently incorporated into the peptidoglycan of S. aureus via the 
sortase A enzyme, SrtA. This chapter will discuss the development of vancomycin-
conjugated SrtA-recognition peptides, which were shown to covalently modify the 
bacterial cell surface through sortase A-mediated surface remodeling. Initially, 
fluorescent handles were conjugated to the peptide-drug complexes, in order to answer 
fundamental questions, such as peptide recognition sequence, optimal linker length for 
incorporation, and potential toxicity. Using these determined conditions, the conjugated 
fluorophore on the peptide-drug complex was exchanged for a DNP antigen moiety to 
facilitate the recruitment of anti-DNP antibodies, readily found in human blood serum. 
The studies presented in this chapter demonstrate that the incorporation of DNP antigens 
within the bacterial peptidoglycan scaffold enhances the recruitment of endogenous anti-
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DNP antibodies to the bacterial cell surface by nearly four-fold compared to unlabeled 
cells. Furthermore, we show, for the first time, the in vivo selective targeting of S. aureus 
in live C. elegans, a widely used model host to understand bacterial pathogenesis and 
host-pathogen interactions. In conjunction, these results pave the way for a narrow-
spectrum strategy for the destruction of bacterial infections caused by S. aureus (drug-
sensitive and -resistant) through bacterial immunotherapy. 
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3.2 INTRODUCTION 
The cell wall of Gram-positive bacteria has served as a fruitful target for the 
development of antibacterial therapies for decades.1 As discussed previously, Gram-
positive bacteria are surrounded by a mesh-like scaffold of peptidoglycan, which is 
composed of multiple layers of N-acetylglucosamine (NAG) and N-acetylmuramic acid 
(NAM) glycan strands that are cross-linked by oligopeptides and provides bacteria with 
immense structural support.2 Due to the critical role of the cell wall during cellular 
growth and division, molecules that interfere with the necessary enzymatic processes 
related to peptidoglycan synthesis have become some of the most successful antibiotic 
agents. Additionally, cell walls come in direct contact with the human hosts, a feature 
that can be exploited by the immune system in the detection and eradication of these 
pathogens. The remodeling of bacterial surfaces using surface-homing antibiotics holds 
considerable potential as a unique and targeted method to modulate the immune response 
by host organisms. As such, we explored the possibility of utilizing the antibiotic, 
vancomycin, as a means to target the surface of Gram-positive bacteria. We designed 
vancomycin-antigen conjugates, in order to decorate the bacterial surface with an 
immune stimulant. The potential as an antigen-conjugated surface displaying molecule is 
of great interest albeit concentration must remain below the minimal inhibitory 
concentration (MIC) of the bacteria. We became interested in designing a surface-
remodeling method that would (1) increase the number of DNP epitopes against 
pathogens that display reduced D-Ala-D-Ala content on mature PG scaffolds, (2) generate 
covalent tags onto the PG scaffold and (3) conduct as a narrow-spectrum drug.  
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We aimed to target S. aureus, and explored the possibility of combining 
vancomycin with a peptidic recognition motif specific to S. aureus. The cell wall of S. 
aureus is very diverse and plays many important roles in the establishment of various 
infectious diseases. As such, the bacteria have devised methods for covalently decorating 
their cell wall with surface proteins, which can be involved in pathogenicity. S. aureus 
lack pili or fimbrial structures and instead rely on surface protein-mediated adhesion to 
host cells or invasion of tissues as a strategy to escape immune defenses.3 In order to 
engage this strategy, this facultative anaerobe decorates its cell surface with a diverse set 
of virulence factors (e.g., exotoxins, exoenzymes, and adhesins) via sortase A (SrtA) 
mediated transpeptidation.4,5 Critical for gaining entry into and colonization in host 
tissues, SrtA transpeptidase is a surface-bound enzyme that attaches bacterial proteins 
onto the PG scaffold of S. aureus (Figure 3.1).6  
In anchoring proteins, sortase A recognizes the short, LPXTG peptide motif 
(where X is any amino acid) and catalyze the acyl-transfer onto lipid II of S. aureus.4 As 
the PG monomeric unit from lipid II is loaded onto the existing PG scaffold, so will the 
anchored protein (Figure 3.1).7 After continued PG biosynthesis, the anchored protein 
will eventually be presented at the cell surface. Spiegel and coworkers have previously 
shown that S. aureus cells treated with fluorescently labeled LPXTG peptides resulted in 
the labeling of bacterial surfaces.8 Furthermore, the conjugation of fluorescein to the N-
terminus of LPXTG and subsequent labeling of the bacterial surface, allowed for the 
recruitment of anti-FITC antibodies to S. aureus.9 
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Although these results highlight the potential in using SrtA-based peptide 
sequences to install unnatural handles on cell surfaces, the concentrations required for 
efficient labeling are not physiologically relevant (0.5-1 mM during overnight 
incubation). These high concentrations are necessary due to the nature of the 
transpeptidase reaction carried out by SrtA (high KM), whereby both of its substrates are 
highly concentrated at the cell surface. Coinciding with the work described in this thesis, 
the reporting of the covalent conjugation of vancomycin to LPXTG was shown to bring 
the substrate peptide to its partner, lipid II, based on the ability of vancomycin to 
Figure 3.1 Remodeling of Bacterial Surface via Sortase A. The transpeptidase 
recognizes a SrtA specific peptide sequence (LPXTG). A cysteine in the active site of 
SrtA attacks the amide bond between the glycine and threonine residues to generate an 
acyl enzyme intermediate. Further reaction of this intermediate with the nucleophilic 
amine of a pentaglycine crosslinking oligopeptide of lipid II anchors the secreted proteins 
to the membrane. As the PG monomeric unit from lipid II is loaded onto the existing PG 
scaffold, so will the anchored protein. After additional PG biosynthesis, the anchored 
protein will eventually be presented at the cell surface. Nature Reviews Microbiology 9, 
166-176 (March 2011). 
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associate with the D-Ala-D-Ala dipeptide on lipid II.10 By increasing the effective 
concentration of the LPXTG, efficient SrtA mediated tagging was possible at low 
micromolar concentrations. We set out to develop a potentially novel immunotherapy 
strategy by exploiting the propensity of bacteria to incorporate exogenous Srt A 
recognition peptides into their peptidoglycan that are conjugated to vancomycin 
displaying antibody-recruiting haptens (Figure 3.2). We hypothesized that a synthetic 
immunology approach could provide a highly efficient method for developing alternative 
antibiotic agents.  
 
 
 
 
 
 
Figure 3.2 Schematic Representation of S. aureus Immunotherapy. S. aureus is 
incubated with sortase A recognition peptides conjugated to vancomycin-DNP. The DNP 
epitope is the antigen which is then covalently bound to the peptidoglycan surface of S. 
aureus. Following the labeling, the binding of anti-DNP IgG antibodies leads to the 
eventual clearance by the immune system.
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3.3 RESULTS AND DISCUSSION  
3.3.1. Fluorescent Labeling of S. aureus using vancomycin-BODIPY 
Vancomycin, and related glycopeptides, imparts cytotoxicity by binding to the 
terminal D-Ala-D-Ala found on the PG stem peptide. As mentioned, the PG layer of the 
cell wall is rigid due to its highly cross-linked structure. As new layers of PG are the 
synthesized, new building blocks of peptidoglycan get inserted (monomers of N-
acetylmuramic acid and N-acetylglucosamine) into the membrane. Vancomycin binds to 
the building blocks of the peptidoglycan and prevents the transpeptidase from acting on 
these new formed blocks and thus prevents cross-linking of the peptidoglycan layer. By 
causing the peptidoglycan layer to be less rigid and more permeable, vancomycin 
addition eventually leads to the death of the bacteria (Figure 3.3). Due to the antibiotic’s 
surface homing ability, we hypothesized that we could exploit the natural tendency of the 
antibiotic as a synthetic immunology approach.  
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Figure 3.3 Mechanism of Vancomycin. Penicillin binding proteins (PBPs) rest on 
peptidoglycan and are responsible for the crosslinking between N-acetylglucosamine (NAG) 
and N-acetylmuramic (NAM) chains. Once vancomycin has irreversibly bound to D-Ala-D-
Ala, PBPs are unable to recognize the site and connect the oligopeptide via their pentaglycine 
chains. (Mcstrother, Vancomycin resistance.svg April 9, 2011) 
vancomycin 
interferes with 
PG crosslinking  
Vancomycin
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In assessing the binding affinity to the surface of S. aureus, we utilized a 
fluorescent vancomycin conjugate, vancomycin-BODIPY. S. aureus cells were incubated 
in medium supplemented with vancomycin-BODIPY (4 µg / mL) for 30 min at 37 °C. 
After allotted incubation time, cells were washed and fluorescence was quantified via 
flow cytometry at indicated time points (Figure 3.4). We observed a decrease in 
fluorescence in the first 5 min suggesting the dissociation of vancomycin-BODIPY from 
the surface of the bacteria. Due to this, we explored the use of a covalent method for 
installing vancomycin antigen conjugates on the surface of bacteria. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Vancomycin-BODIPY Dissociation from S. aureus Surface. 
Flow cytometry analysis of vancomycin-BODIPY-labeled S. aureus cells 
after indicated times. Data are represented as mean + SD (n = 3). 
52 
 
3.3.2 SrtA-mediated Incorporation in S. aureus 
Some surface proteins require SrtA for the covalent anchorage to the 
peptidoglycan of Gram-positive bacteria. The enzyme recognizes secreted proteins 
bearing a specific sortase motif, Leu-Pro-X-Thr-Gly (LPXTG), and Leu-Pro-X-Thr-
Gly/Leu-Pro-X-Thr-Ala-Ala (LPXTG/LPXTAA), for Staphylococcus aureus and 
Streptococcus pyogenes, respectively (where X is any amino acid). Other Gram- positive 
bacteria will also possess sortase enzymes, yet may have different recognition motifs11 
and substrate requirements.12 Although the natural sortase substrate is the LPETG motif 
in S. aureus, the use of methionine in the central position of the pentapeptide 
demonstrated enhanced cell surface labeling.7 However, due to the role of SrtA as a 
housekeeping enzyme responsible for covalently modifying the peptidoglycan with 
proteins, the Km of the enzyme is high.13 Thus, the required LPXTG-motif containing 
peptide concentration needed for labeling requires millimolar concentrations.  
Initially, we synthesized peptides to establish the baseline values for efficient 
SrtA-mediated incorporation into the peptidoglycan of S. aureus. All fluorescently 
labeled SrtA recognition peptides were built via solid-phase peptide synthesis using 
standard Fmoc-chemistry (Scheme 3.1). We constructed two variants, FITC-KLPMTG-
NH2 and FITC-KLPETG-NH2, and a control peptide exhibiting a scrambled SrtA 
sequence, FITC-KMGTLP, employing the fluorescein (FITC) fluorophore which is 
compatible for solid-phase synthesis. S. aureus cells were incubated overnight in medium 
supplemented with 1 mM of FITC-KLPMTG, FITC-KLPETG or control peptide, FITC-
KMGTLP.   
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Scheme 3.1 Synthesis of FITC Conjugated SrtA Recognition Peptides. Peptides were 
synthesized using Fmoc-protected amino acids conjugated on Sieber resin. FITC 
fluorophore was conjugated to the N-terminus. Following conjugation, deprotection of the 
N-terminus of lysine and TFA cleavage from the resin afforded FITC Conjugated SrtA 
Recognition Peptides. Synthesis shown for FITC-KLPMTG; all peptides underwent same 
synthetic procedure.   
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The bacteria cells were washed and analyzed for the acquisition of green 
fluorescence from the fluorescein fluorophore. Consistent with previous reports, we 
observe roughly a 2-fold increase in surface labeling exposed to FITC-KLPMTG over 
bacteria exposed to FITC-KLPETG. Both the unlabeled bacteria and bacteria treated with 
the scrambled control displayed reduced fluorescence (Figure 3.5).  
 
 
Figure 3.5 Incorporation of FITC Conjugated SrtA Recognition Peptides. 
Flow cytometry analysis of S. aureus incubated overnight in the presence of 
LB alone, and LB supplemented with 1 mM of FITC-KLPETG or 1 mM of 
FITC-KLPMTG or 1 mM of FITC-KMGTLP. Data are represented as mean + 
SD (n = 3). 
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Next, we visualized the labeled S. aureus via fluorescence microscopy and 
observed a uniform fluorescence signal throughout the cell (Figure 3.6). We believe the 
difference in fluorescence levels in bacteria treated with different peptide sequences 
suggests a specific process of incorporation. In this case, we believe SrtA activity is 
responsible for selectively incorporating the LPMTG-containing peptide into the cell wall 
over the scrambled control.  
 
 
 
 
 
Figure 3.6 DIC and Fluorescent Microscopy Image of FITC-KLPMTG 
Labeled S. aureus. S. aureus were incubated in LB supplemented with 1 
mM FITC-KLPMTG overnight at 37 °C. Cells were washed and imaged. 
Scale bar represents 1μm. 
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3.3.3 Vancomycin-conjugated SrtA Recognition Peptide Incorporation in S. aureus 
Next, we constructed fluorescent peptides consisting of the LPMTG motif and the 
antibiotic, vancomycin. In particular, we varied the linker between the LPMTG and 
vancomycin to establish the optimum linker length (Figure 3.7). The spacer between 
these two units should be long enough to accommodate the binding of the D-Ala-D-Ala 
by vancomycin and the docking of the LPMTG onto the SrtA active site.  
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A 
Figure 3.7 Cartoon representation of SrtA incorporation of Vancomycin-
peptide conjugates. (A) Scheme depicting the anchoring of sortase A peptides 
onto PG. The presence of vancomycin positions the conjugate at the site of the 
sortase A enzyme. Due to this the effective concentration of the sortase A peptide 
substrate increases causing swift incorporation and transfer onto Lipid II. (B) 
Structure of sortase-vancomycin conjugates. 
B 
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In the absence of structural data, we sought to empirically establish the optimum 
tether by evaluating a small panel of poly ethylene glycol (PEG) spacers. The high 
flexibility and solubility of PEG should be ideal for the bridging of LPMTG with 
vancomycin. We constructed several peptides with this backbone, FITC(PEG)-K(PEGn-
Vanc)-LPMTG, where n = 0, 1, 2, 3 (Table 3.1). We anticipated building this panel of 
peptides completely on solid support. However, vancomycin is deglycosylated in the 
presence of trifluoroacetic acid, eliminating the vancosamine and vancosaminyl-O-
glucose sugars.14,15  
 
 
 
 
Table 3.1 List of Synthesized Vancomycin-SrtA peptide conjugates.  
Compound : PEG Linker : Abbreviation :
FITC(PEG)-KLPMTG 0 FITC-PEG0
FITC(PEG)-K(PEG)-LPMTG 1 FITC-PEG1
FITC(PEG)-K(PEG2)-LPMTG 2 FITC-PEG2
FITC(PEG)-K(PEG3)-LPMTG 3 FITC-PEG3
FITC(PEG)-K(Vanc)LPMTG 0 FITC-PEG0Vanc
FITC(PEG)-K(PEG-Vanc)-LPMTG 1 FITC-PEG1Vanc
FITC(PEG)-K(PEG2-Vanc)-LPMTG 2 FITC-PEG2Vanc
FITC(PEG)-K(PEG3-Vanc)-LPMTG 3 FITC-PEG3Vanc
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To confirm, we dissolved vancomycin in 95% TFA and obtained a HPLC trace 
(Figure 3.8). We overlaid the trace with the traces of pure vancomycin and pure 
vancomycin aglycon (vancomycin without the sugars). As seen in the trace, even pure 
vancomycin is susceptible to the 0.1% TFA added in the HPLC solvents. Therefore, the 
series of constructs were built using a combination of solid and solution phase 
chemistries and purified using 0.001% TFA HPLC solvents, due to the high sensitivity of 
vancomycin towards acidic conditions.  
 
 
Figure 3.8 Vancomycin Acid Susceptibility. Vancomycin treated with 95% TFA 
(red trace) displays three peaks in the HPLC trace, depicting the vancomycin peak 
(center), the sugars (left) and the vancomycin aglycon (right). Vancomycin (black 
trace) is susceptible to HPLC acidic solvents displaying the vancomycin aglycon 
peak (right).  
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Vancomycin was coupled to the primary amine of PEG linker or directly to the 
lysine side chain, resulting in the final constructs (Scheme 3.2). All compounds were 
purified via reverse phase high performance liquid chromatography (RP-HPLC). Masses 
were confirmed using either electrospray ionization mass spectrometry (ESI-MS) or 
matrix assisted laser desorption/ionization time of flight mass spectrometry (MALDI-
TOF MS). 
S. aureus was incubated overnight in medium supplemented with 5 μM of each 
construct. The bacteria cells were washed and analyzed by flow cytometry. We observed 
a 30-fold increase in fluorescence for bacteria exposed to FITC-PEG0Vanc and FITC-
PEG1Vanc over unlabeled bacteria (Figure 3.9). This increase is attributed to the 
presence of vancomycin. The peptides not conjugated to vancomycin displayed very little 
to no fluorescence, indicating that vancomycin is needed to position the peptide near SrtA 
at the cell membrane. Lipid II, the target of vancomycin, is anchored on the cell 
membrane and is the recipient of the sortase cargo. We observed a loss in fluorescence 
for the peptides with a longer linker between the sortase A motif and vancomycin. This 
indicates length dependence between the motif and the antibiotic. The low levels of 
fluorescence associated with these samples may have resulted from nonspecific binding 
of the peptide construct to the bacterial surface or from low levels of intracellular 
accumulation. 
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Next, we probed the distance between the sequence motif and the fluorophore. 
We constructed another peptide incorporating an additional PEG group before the FITC 
fluorophore (Table 3.2).  
 
Figure 3.9 Vancomycin-conjugated SrtA Recognition Peptide 
Incorporation in S. aureus. Flow cytometry analysis of S. aureus cells 
incubated overnight in LB supplemented with panel of fluorescent 
conjugates at 5 µM. Data are represented as mean + SD (n = 3). 
Table 3.2 List of Synthesized Vancomycin-SrtA peptide conjugates.  
Compound : PEG Linker : Abbreviation :
FITC(PEG2)-K(PEG)LPMTG 1 FITC-2PEG1
FITC(PEG2)-K(PEG-Vanc)-LPMTG 2 FITC-2PEG1Vanc
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Incubating S. aureus with 5 µM of FITC-PEG1Vanc or FITC-2PEG1Vanc 
overnight led to a 2.5 – fold increase in fluorescence for the FITC-2PEG1Vanc treated 
bacteria over the FITC-PEG1Vanc treated bacteria (Figure 3.10). Thus, the addition of 
the spacers before the fluorophore handles seems to aid in incorporation efficiency.  
  
We believe this incorporation suggests a specific process of incorporation by Srt 
A, and therefore, should only label Gram – positive bacteria where Srt A is heavily 
expressed. To test this, we incubated 2PEG1Vanc with several different bacteria of 
varying Srt A expression levels. After overnight incubation, the bacteria were washed and 
fluorescence was quantified via flow cytometry. As evident from the fluorescence levels, 
2PEG1Vanc is incorporated into S. aureus to the greatest extent (Figure 3.11).  
Figure 3.10 Vancomycin-conjugated SrtA Recognition Peptide Incorporation in 
S. aureus. Flow cytometry analysis of S. aureus cells incubated overnight in LB 
supplemented with panel of fluorescent conjugates at 5 µM. Data are represented as 
mean + SD (n = 3). 
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Figure 3.11 Vancomycin-conjugated SrtA Recognition Peptide 
Incorporation in Various Bacterial Strains. Flow cytometry analysis of 
bacterial cells incubated overnight in LB supplemented with FITC-2PEG1 or 
FITC-2PEG1Vanc at 5 µM. Data are represented as mean + SD (n = 3).  
 
As expected, the Gram-negative E. coli failed to incorporate the construct. 
Listeria monocytogenes displayed low incorporation levels, as the bacteria boasts a high 
expression of sortase B over sortase A.16 S. epidermidis rely on Srt A-mediated covalent 
modification and non-covalent interactions with surface polymers such as teichoic acids 
to decorated their cell surface.17,18 As such, S. epidermidis displayed the second highest 
fluorescence levels, depicting mild incorporation. Lastly, B. subtilis failed to grow under 
the pressure of 5 µM FITC-2PEG1Vanc. This is due to the high toxicity of vancomycin 
towards B. subtilis. As seen in Figure 3.12, the minimal inhibitory concentration (MIC) 
of vancomycin is 0.39 µg / mL (0.27 μM) in B. subtilis.   
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As this data shows selective labeling of S. aureus, it favorably compliments the 
use of the construct as a recruitment tool for the host immune system. Moreover, the 
increased length between the fluorophore and the rest of construct favorably compliments 
antibody recruitment to the bacterial cell surface since the antigen location requires 
exposure to the extracellular space. In order to use this technique for antibody 
recruitment, we want to ensure that the peptide becomes incorporated throughout the 
peptidoglycan not just at the site of the target of vancomycin. Vancomycin accumulates 
preferentially at the regions of cell division/growth (concentrated pools of Lipid II 
molecules). If that is the case, then only dividing cells would be labeled with the peptide 
Figure 3.12 Toxicity of Vancomycin in Gram-positive Bacteria. MIC determinations 
were performed in cation-adjusted Mueller-Hinton Broth (CaMHB). The MIC was 
defined as the lowest vancomycin concentration at which visible growth was inhibited 
following 18 h incubation at 37 °C. Data are represented as mean + SD (n = 3).  
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since there is an accumulation of Lipid II during bacterial growth. If vancomycin is solely 
present to bring the peptide closer to sortase A and then the enzyme incorporates it into 
the peptidoglycan, as we assume, then the peptide should be uniform through-out the 
peptidoglycan surface of the bacteria. Using confocal microscopy, cells were imaged 
during two different growth phases: exponential and stationary phase. S. aureus (OD 6.0) 
was incubated with fluorescently-labeled 2PEG1Vanc for 15 min and 4 h. After allotted 
time, cells were washed, fixed and analyzed via fluorescence microscopy. We observed 
septal fluorescence and fluorescence of the bacterial surface after the 15 min incubation 
time (Figure 3.13, top). This is attributed to high concentration of Lipid II during the 
growth phase. However, after 4 h the fluorescence can be seen through-out the surface, 
consistent with SrtA incorporation of the fluorescent construct into the peptidoglycan 
(Figure 3.13, bottom). These results demonstrate the selectivity for S. aureus and the 
uniform display of the construct over the surface of the bacteria. In exploiting this 
selectivity, we sought to conjugate an epitope to the peptide, in order to potentially 
generate a narrow-spectrum immuno-therapy technique for S. aureus.  
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Figure 3.13 DIC and Fluorescent Microscopy Image of FITC-
2PEG1Vanc Labeled S. aureus. Log phase S. aureus were incubated in LB 
supplemented with 5 μM FITC-2PEG1Vanc for 15 min (top) or 4 h (bottom) 
at 37 °C. Cells were washed and imaged. Scale bar represents 1μm. 
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3.3.4 DNP-Conjugate Mediated Opsonization of S. aureus  
The effectiveness of these constructs as an antibody recruitment facilitator was 
assessed by replacing the fluorophore with an immune stimulant epitope. To accomplish 
this, we utilized 2,4-dinitrohpenol (DNP), chosen for the relatively high concentration of 
anti-DNP antibodies in human serum.19 Minding the length requirements determined in 
the previous labeling studies, we synthesized a DNP- displaying construct (Scheme 3.3).  
We synthesized, DNP(PEG2)K(PEG-Vanc)LPMTG (DNP-2PEG1Vanc), with the 
anticipation that SrtA would be able to recognize and incorporate it into the 
peptidoglycan, as with the FITC-labeled peptides. For this set of experiments, we utilized 
a mutant strain of S. aureus (Wood strain), in which endogenous protein A is knocked 
out. Protein A, a surface protein anchored to the cell surface by SrtA, binds to the Fc 
terminus of mammalian immunoglobulins in a nonimmune fashion, causing decoration of 
the staphylococcal surface with antibody.20,21 Protein A is the bacteria’s defense against 
the immune system. For our experiments since the recruitment efficiency is quantified by 
fluorescence the presence of protein A would increase background fluorescence by 
binding to the fluorescent anti-DNP antibodies. The Wood strain was utilized in order to 
clearly show proof-of-concept for antibody recruitment to S. aureus.  Additionally, we 
hypothesized that teichoic acid−based polyanionic polymers (wall teichoic acid and 
lipoteichoic acid) contained within the cell wall of S. aureus may serve to hinder the 
permeation and binding of anti-DNP antibodies to the modified peptidoglycan.22, 23,24 By 
growing the bacteria overnight in the presence of DNP-2PEG1Vanc and tunicamycin, a 
known wall teichoic acid inhibitor, cell surface antibody binding was greatly increased 
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compared to FITC-conjugated anti-DNP binding observed in previous experiments. The 
recruitment capability of the peptide constructs was quantified by fluorescence of FITC-
labeled anti-DNP on the surface of the bacteria. We observed nearly a 15-fold increase 
for S. aureus labeled with the vancomycin-conjugated peptide over S. aureus labeled with 
the non-vancomycin conjugated peptide (Figure 3.14).  
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In order to emulate a more biological representation, we sought to recruit 
antibodies to the surface of methicillin-resistant S. aureus. In order to eliminate the IgG 
binding contribution of protein A, we blocked the surface of the bacteria with polyclonal 
IgG prior to FITC-labeled anti-DNP addition. We observed a 3-fold increase for S. 
aureus treated with the vancomycin-conjugated peptide over unlabeled S. aureus (Figure 
3.15).   
Figure 3.14 Antibody Recruitment to the Surface of S. aureus-Wood 
Strain. Cells were incubated overnight in LB supplemented with indicated 
concentration of specified DNP-conjugate followed by incubation with anti-
DNP antibodies. Data are represented as mean + SD (n = 3). 
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Also, it is worth noting that even at 10 times the recruitment concentration (50 
μM) of DNP-2PEG1Vanc, we observed marginal bacterial growth inhibition (Figure 
3.16). 
 
 
 
 
 
Figure 3.15 Antibody Recruitment to the Surface of S. aureus Sc01. Cells were 
incubated overnight in LB supplemented with 5 µM of DNP-2PEG1Vanc followed 
by incubation with polyclonal IgG. After washings, cells were incubated with anti-
DNP antibodies. Data are represented as mean + SD (n = 3). 
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In addition to antibody recruitment ability, we set out to assess the toxicity of 
DNP-2PEG1Vanc against host mammalian cells. One of the major possible advantages of 
using this peptide construct to target bacteria derives from the fact that it relies upon the 
enzymatic incorporation at the surface of the cell. No mammalian enzymes are known to 
exist and accept –LPXTG substrates, potentially giving this strategy high selectivity. 
Therefore, it is anticipated that in a living organism, administered SrtA substrates would 
be preferentially utilized by bacteria.  
Figure 3.16 DNP-2PEG1Vanc Toxicity towards S. aureus Sc01. S. aureus Sc01 
cells were incubated with varying concentrations of DNP-2PEG1Vanc for 18 h at 
37 °C. Bacterial viability was evaluated by measuring the absorbance at 600 nm. 
Data are represented as mean + SD (n = 3). 
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To evaluate the toxicity of DNP-2PEG1Vanc, HEK293 cells were incubated in the 
presence of varying concentrations of construct for 24 h and analyzed by standard 
viability assays (Figure 3.17). At all concentrations examined, we observed no significant 
loss of viability, thus highlighting an important feasibility consideration of our strategy. 
 
 
 
Figure 3.17 Induced Mammalian Toxicity. HEK293 cells were incubated for 24 
hours in the absence or the presence of increasing concentrations of construct. 
Cellular viability was evaluated with MTT by measuring absorbance at 580 nm. 
Data are represented as mean + SD (n = 3). 
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3.3.5 In vivo Labeling of S. aureus Sc01 in C. elegans  
We anticipate that this strategy can be a worthwhile model to apply synthetic 
immunology in in vivo models in the future. To test this feasibility, we first sought to 
determine if our lead compound, FITC-(PEG2)K(PEG-Vanc)LPMTG, can label S. aureus 
Sc01 in vivo. In pursuing live labeling, we chose the model organism, Caenorhabditis 
elegans (C. elegans).  
On the day of experiments, C. elegans were washed with M9 buffer and incubated 
with 10% LB broth and 10% S. aureus Sc01 in M9 buffer at room temperature for 4 h. 
After washing the C. elegans with M9 buffer, they were resuspended in M9 buffer 
supplemented with 10% LB broth and either 50 μM FITC-(PEG2)K(PEG-Vanc)LPMTG 
(FITC-2PEG1Vanc) or 50 μM FITC(PEG2)K(PEG)LPMTG (FITC-2PEG1) and 
incubated for an additional 30 min at room temperature. The C. elegans were harvested, 
washed, resuspended in 10 mM sodium azide and analyzed by confocal microscopy. 
Remarkably, we observed in vivo labeling of S. aureus Sc01 in C. elegans treated with 
FITC-2PEG1Vanc (Figure 3.18). We observed no bacterial labeling with treatment of 
FITC-2PEG1. To our knowledge, this is the first SrtA mediated labeling of methicillin-
resistant S. aureus in C. elegans.  
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Figure 3.18 in vivo Labeling of S. aureus Sc01 in C. elegans. Confocal microscopy 
images of S. aureus Sc01 in C. elegans. C. elegans were infected with bacteria for 4 h 
at room temperature. C. elegans were washed to remove any bacteria not ingested. C. 
elegans were subsequently incubated with 50 µM of either FITC-2PEG1Vanc or 
FITC-2PEG1 for 30 min at room temperature. After washing and treatment with 10 
mM sodium azide, C. elegans were imaged with confocal microscopy. Scale bars = 
10 µm.   
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3.3.6 SrtB-mediated Incorporation in L. monocytogenes 
 Lastly, we explored whether the use of specific sortase incorporation could be 
expanded to other sortases present in other bacteria. Whereas SrtA acts on most of the 
proteins in the peptidoglycan fraction, sortase B (SrtB) appears to target minor amounts 
of surface polypeptides. Motifs recognized by SrtB are defined by the consensus 
sequence, -NXZTN, where X can be any amino acid and Z typically lends to a charged 
amino acid.16 Noteworthy, the sorting motif recognized by SrtB has been experimentally 
tested only with the surface protein IsdC involved in iron acquisition. IsdC of S. aureus 
and Bacillus anthracis are recognized by SrtB at NPQTN and NPKTG motifs, 
respectively.25, 26 Differences in sequence motif are dependent on the organism/substrate 
with the aforementioned exceptions, experimental data supporting the recognition of 
other sorting motifs are lacking.  
 Listeria monocytogenes, a ubiquitous food-borne Gram-positive bacterium, 
interacts with host cells through a number of surface proteins to induce pathogenesis of 
listeriosis. L. monocytogenes contains and utilizes both, SrtA and SrtB. Mariscotti et al. 
reported elegant work in identifying the motifs recognized by SrtB of L. monocytogenes 
and unveiled the unique capacity of L. monocytogenes SrtB for recognizing a sorting 
motif lacking the invariant proline at position (2), exemplified by sequence, -NAKTN.16 
We constructed a FITC-conjugated SrtB recognition peptide and incubated L. 
monocytogenes overnight in medium supplemented with FITC(PEG)NAKTN. After 
analysis, we observed approximately a 30-fold increase in surface labeling in bacteria 
exposed to 1 mM FITC(PEG)NAKTN over unlabeled bacteria (Figure 3.20).  
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From this data, we anticipate that selective tagging of L. monocytogenes through 
SrtB mediated incorporation can be utilized as another bacterial immunotherapy 
technique. 
 
 
 
 
Figure 3.19 SrtB-mediated Fluorescent Peptide Incorporation in Listeria 
monocytogenes. Flow cytometry analysis of L. monocytogenes cells incubated 
overnight in LB supplemented with FITC(PEG)NAKTN at designated 
concentrations. Data are represented as mean + SD, (n = 3). 
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3.4 CONCLUSION 
The utilization of immunomodulatory strategies for combating pathogenic 
bacterial infections represents an attractive alternative to traditional antibiotic 
therapeutics. In this strategy, we show specific and selective targeting of methicillin-
resistant S. aureus for clearance by the host immune system.  This technique exploits the 
SrtA mediated incorporation of vancomycin-conjugated peptides. We show that a panel 
of fluorescently labeled vancomycin-conjugated SrtA recognition peptides is readily 
incorporated into the peptidoglycan of S. aureus within 15 min of treatment. From these 
studies, we empirically observed peptidoglycan incorporation dependent on peptide 
linker length. We hypothesize that this length restriction arises from the distance between 
the sortase A enzyme and the vancomycin binding site, Lipid II. We identified that FITC-
(PEG2)K(PEG-Vanc)LPMTG is the optimal construct for efficient selective incorporation 
into the cell wall S. aureus, while achieving minimal incorporation in S. epidermidis, and 
achieving marginal to no incorporation in L. monocytogenes, E. coli, and B. subtilis.  
We show that DNP(PEG2)K(PEG-Vanc)LPMTG is readily incorporated into the 
peptidoglycan and permits the recruitment of anti-DNP antibodies to the cell surface of 
methicillin-sensitive S. aureus and methicillin-resistant S. aureus. Furthermore, we show, 
for the first time, the successful SrtA mediated labeling of methicillin-resistant S. aureus 
in C. elegans.  
Through these studies, we illustrate a strategy that has the potential to be an 
effective therapy against bacterial infections caused by S. aureus. We anticipate that the 
unique metabolic labeling process of this strategy may reduce the potential for the 
emergence of resistance. S. aureus bacteria rely on SrtA to metabolically incorporate 
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almost 20 different sortase substrates, necessary for cellular evasion, colonization, and 
consequently, pathogenicity. By employing this essential method of incorporation, the 
chance of rapid bacterial resistance is not expected. Moreover, the use of SrtA mediated 
incorporation significantly limits this strategy to S. aureus, making this an appealing 
platform for narrow-spectrum bacterial immunotherapy. 
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Chapter 4 
Synthetic Immuno-Attractants against Gram-Negative Pathogens 
 
4.1 ABSTRACT  
 The number of drug-resistant bacterial infections has been rapidly rising and may 
soon approach epidemic levels. For these reasons, there is an urgent need for novel 
antimicrobial modalities to be developed. The emergence of multi-resistant bacteria that 
are part of the ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella 
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter 
species) group of pathogens is a particularly acute challenge to the healthcare system. 
ESKAPE pathogens are the leading cause of nosocomial infections worldwide. This 
chapter will discuss our efforts in re-engaging the immune system towards Gram-
negative pathogenic bacteria via synthetic molecules that remodel bacterial cell surfaces 
with immune cell attractants. More specifically, we built conjugates composed of 
polymyxin B, an antibiotic that inherently homes to bacterial cells surfaces, linked to 
antigenic epitopes that engage endogenous antibodies. Given the inherent antimicrobial 
activity of polymyxin, we additionally showed that these agents display dual activities 
against bacteria. By leveraging the power of the immune system in clearing pathogens, 
this new class of molecules was shown to uniquely target Gram-negative bacteria and, 
additionally, potentiate existing FDA-approved antibiotics. We hope to establish this 
approach as a viable treatment option and further refine this methodology to address the 
clinical challenge of Gram-negative bacterial pathogens.  
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4.2 INTRODUCTION 
The rapid surge in drug-resistant bacterial infections has now become one of the 
primary public health crises of the 21st century, consequently, driving a renewed effort to 
find antibiotics with unique mechanisms of action. As mentioned in Chapter 1, the World 
Health Organization considers Gram-negative pathogens high priority target areas. Every 
year in the United States alone, over two million people are afflicted with bacterial 
infections resistant to FDA-approved antibiotics. Most alarming is the emergence of 
multidrug Gram-negative pathogenic bacteria, including strains that are resistant to all 
currently available antibiotics.3 The four most problematic infections are caused by drug 
resistant Klebsiella pneumoniae (K. pneumoniae), Acinetobacter baumannii (A. 
baumannii), Pseudomonas aeruginosa (P. aeruginosa), and Escherichia coli (E. coli). 
The paucity of drugs against these pathogens means that we run the risk of entering a 
post-antibiotic era. 
Compared to Gram-positive organisms, Gram-negative bacteria possess an outer 
membrane (OM) that lies to the exterior of the cytoplasmic membrane bilayer. The 
additional layer serves as a formidable barrier to permeation of small molecule antibiotics 
and larger biomacromolecules.4 Partly for these reasons, there are currently fewer 
antibiotics that are active against Gram-negative bacteria. As mentioned in Chapter 3, 
bacterial cell surfaces play crucial roles in the normal physiology and pathogenicity (in 
the case of pathogenic bacteria) of these organisms. Proteins and structural polymers at 
the cell surface are actively involved in bacterial adhesion, colonization, and engagement 
with the host immune cells.5,6 We envisioned a molecule that successfully targeted one of 
the structural polymers on the surface of Gram-negative bacteria.   
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We expanded on our recent finding that we can decorate the surface of Gram-negative 
bacteria using antibiotic conjugates that home to and associate with bacterial cell 
surfaces. Due to the vast surface area of bacterial cell surfaces and their exposure to the 
host organism, it is the principal bacterial structure recognized by the human immune 
system.  
We reasoned that grafting immune cell attractant tags on bacterial cell surfaces 
would result in effective recruitment of immune cells. In the previous chapter, we had 
targeted the modification of bacterial peptidoglycan (PG) for the installation of antibody 
recruiting haptens. Although Gram-negative bacteria also have PG scaffolds and they are 
remodeled via synthetic cell wall analogs, the 
presence of the OM prevents any engagement 
with immune cells. Instead, we had to explore 
a different mode of surface modification. 
Gram-negative bacterial cells generally 
possess negatively charged surfaces due to the 
high abundancy of lipopolysaccharide (LPS). 
Lipid A, an essential lipid component of LPS, 
is composed of a phosphorylated 
diglucosamine unit connected to lipid chains (Figure 4.1).  
The naturally occurring lipopeptide antibiotic, polymyxin B (PMB), is unique in 
the ability to associate with Lipid A with high affinity and specificity. PMBs are 
comprised of hydrophobic and hydrophilic domains, both of which are pivotal for their 
antibacterial activity. The core PMB scaffold consists of a cyclic hexapeptide linked to a 
Figure 4.1 Structure of LPS. 
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linear tripeptide with an N-terminal fatty acyl tail (Figure 4.2). Five L-α,γ-diaminobutyric 
acid (Dab) residues decorate the scaffold, the primary amines of which are positively 
charged at 
physiological pH 
(7.4). Two 
hydrophobic residues 
in positions 6 and 7 of 
the cyclic hexapeptide 
form an intermediary 
hydrophobic segment 
that breaks the 
succession of cationic 
Dab residues. 
Specifically, the 
cationic cyclic peptide 
binds to negatively 
charged Lipid A on bacterial OMs and the aliphatic fatty acid tail anchors into the0- 
membrane (Figure 4.2).7 PMB is thought to impart its antibacterial activity by binding to 
the OM surface and destabilizing the OM layer – although the exact mechanism has yet 
to be fully elucidated.8,9 These features made PMB an attractive target for our surface 
remodeling strategy, as both of these structural components were integrated into our 
design to establish the optimum combination of inherent antimicrobial activity in synergy 
with immunomodulation.  
Figure 4.2 Representation of PMB and LPS Binding. 
Polymyxin B and LPS bind through ionic forces and 
strong hydrophobic forces. 
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Herein, we describe a strategy aimed at targeting bacterial cells for destruction via 
small molecule conjugates that specifically home to Gram-negative bacterial cell 
surfaces. By exploiting surface exposed features (e.g., Lipid A) unique to Gram-negative 
bacteria, we hypothesized that heterobifunctional agents composed of Polymyxin B 
(PMB) would lead to the specific surface presentation with epitopes that engage various 
components of the immune system (e.g., antibodies and primary immune cells). The use 
of surface homing agents that inherently possess antimicrobial activity represents a 
significant advance due to the potential synergism between (1) the direct bactericidal 
activity of the homing beacon and (2) the engagement of immune system. Combined, we 
showed that these agents effectively target Gram-negative pathogen in two distinct ways 
with minimal toxicity towards host cells. 
 
 
 
Figure 4.3  Schematic Representation of Gram-negative 
Bacterial Immunotherapy. Gram-negative bacteria are incubated 
with PMB-hapten conjugates. Following the labeling, the binding 
of anti-DNP IgG antibodies leads to the eventual clearance by the 
immune system. 
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4.3 RESULTS AND DISCUSSION 
4.3.1 Fluorescent Labeling of E. coli using PMBN-FITC  
In collaboration with the Regen Group, they synthesized a fragment of PMB 
known as PMB nonapeptide (PMBN) (Figure 4.4). PMBN is devoid of the membrane-
disrupting fatty acid tail but, critically, retains the cyclic heptapeptide responsible for 
association to Lipid A.10, 11 The smaller PMBN fragment has attenuated antimicrobial 
activity, which can be useful in isolating the effect of surface-homing in our strategy. We 
tested the toxicity of PMBN to E.coli and determined the MIC to be 40 μg/mL. 
We generated a fluorescent PMBN 
by coupling fluorescein to (BOC)-
protected PMBN (Scheme 4.1). After 
purification and removal of the protecting 
groups, the construct was incubated 
overnight with E.coli to assess its ability to 
label the cell surface. E. coli was grown in 
LB supplemented with increasing 
concentrations of the PMBN-FITC (0 – 
200 µM). The cells were harvested, 
washed, and analyzed via flow cytometry. 
By quantifying fluorescence, we observed 
a roughly 30-fold increase in fluorescence for bacteria exposed to 40 µM of the construct 
(Figure 4.5). Concentrations of greater than 40 µM of the construct were toxic to the 
bacteria cells as assessed by optical density (600 nm).  
Figure 4.4 Structures of Polymyxin B and 
PMB-Nonapeptide (PMBN).   
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Scheme 4.1 Synthesis of PMBN-FITC. (BOC)-PMBN (1 eq.) was 
reacted with fluorescein isothiocyanate (1.5 eq.) in DMF with N,N-
diisopropylethylamine (DIEA) (2 eq.). After acidic treatment to remove 
the –BOC protecting groups, the compound was purified via normal phase 
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Given the nature of the interaction between PMBN and LPS on cell surfaces, 
which is independent of cell growth/division, we sought to establish labeling to cells in 
stationary phase. Bacterial cells at stationary phase display dramatically lower metabolic 
rates and do not undergo extensive cell growth and division.12 A large fraction of the 
currently available antibiotics fail to effectively clear bacterial pathogens at stationary 
phase due to their reliance on processes related to cell growth and division.13 Therefore, 
developing a molecule that elicits a therapeutic effect against stationary phase bacteria 
would be valuable in the treatment of latent bacterial infections.  
Figure 4.5 PMBN-FITC Labeling of E. coli. Flow cytometry analysis of 
E. coli incubated overnight in the presence of LB alone, and LB 
supplemented with increasing concentrations of PMBN-FITC. Data are 
represented as mean + SD (n = 3). 
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We incubated stationary phase (OD = 1.4) E. coli in media supplemented with 40 
µM PMBN-FITC at 37 °C. At indicated time points, the bacteria were harvested, washed, 
and analyzed by flow cytometry. We observed an increased in fluorescence over time, 
with maximum fluorescence after 2 h of incubation (Figure 4.6). After 2 h, a reduction in 
fluorescence is observed. This may arise from stationary phase bacteria death due to lack 
of nutrients.  
 
 
 
 
 
Figure 4.6 PMBN-FITC Labeling of E. coli over Time. Flow cytometry data of 
stationary phase E. coli incubated with 40 μM PMBN-FITC for indicated time 
points in LB media. Data are represented as mean + SD (n = 3). 
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In further understanding how PMBN-FITC interacts with the cell surface, we 
sought to determine the persistence of association of the construct to the bacterial surface. 
Stationary phase E. coli was incubated with 40 μM PMBN-FITC for 2 h at 37 °C. After 
harvesting and washing, the bacteria were resuspended in phosphate buffer saline (PBS) 
and the loss of fluorescence was monitored over time. We did not observe immediate 
dissociation of the construct from the bacterial surface (Figure 4.7).  
 
 
 
 
Figure 4.7 PMBN-FITC Dissociation from E. coli Surface. Flow cytometry data 
of stationary phase E. coli incubated with 40 μM PMBN-FITC for 2 h, then 
incubated in PBS for indicated time before analysis. Data are represented as mean + 
SD (n = 3). 
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Next, we explored how the addition of cations would affect the labeling ability of 
PMBN-FITC to the surface of the bacteria. As mentioned, polymyxin B exerts its 
antimicrobial activity through an electrostatic interaction of the cationic Dab residues 
with the negatively charged phosphate groups of lipid A of LPS. This complex formation 
displaces divalent cations (Ca2+ and Mg2+) that bridge adjacent LPS molecules.14, 15, 16 
Therefore, we expected that salt concentrated media would negatively affect the labeling 
efficiency of PMBN-FITC to the E.coli surface by competing for the negatively charged 
phosphate groups of lipid A. 
We incubated stationary phase (OD = 1.4) E. coli in the presence of 40 µM 
PMBN-FITC for 2 h in medium of differing salt concentrations. We utilized Luria Broth 
(LB) as a control. LB is the complete growth media for E. coli. Mueller Hinton (MH) 
Broth is the broth of choice for antimicrobial susceptibly testing. It is commonly used in 
the micro dilution technique of assessing minimal inhibitory concentration of antibiotics 
and contains 11.5 mg/L Ca2+ and 2.5 mg/L Mg2+. We further supplemented Mueller 
Hinton (MH) Broth with additional cations, resulting in a final concentration of 21.5 
mg/L Ca2+ and 12.5 mg/L Mg2+.   
Upon fluorescent analysis, we observed the expected trend of decreased labeling 
efficiency with increased salt concentration (Figure 4.8). The data shows efficient 
PMBN-FITC labeling of E. coli over time when incubated with LB media. Conversely, as 
the concentration of calcium and magnesium increases, and the propensity for 
competition increases, the level of fluorescence decreases, indicating a lack of efficient 
labeling of the construct of the E. coli surface. From this data, we also observe a steady 
increase in fluorescence for E. coli incubated with the construct in LB media.   
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 Lastly, we visualized the labeled E. coli via fluorescent microscopy. We observed 
a uniform fluorescence signal along the cell surface (Figure 4.9). We observed heavily 
concentrated signal at the poles of the bacteria, a finding that is consistent with 
polymyxin B nonapeptide bacterial surface labeling. 17, 18 
Taken together, we believe our modification of polymyxin B does not interrupt its 
ability to interact with the surface of E. coli. We observed PMBN-FITC labeling of the E. 
coli surface, through interaction with the negatively charged LPS. Furthermore, we show 
that PMBN-FITC labels stationary phase E. coli. As mentioned, a large fraction of the 
currently available antibiotics fail to effectively clear bacterial pathogens at stationary 
Figure 4.8 Cation Effect on PMBN-FITC Labeling of E. coli. Flow cytometry 
data of stationary phase E. coli incubated with 40 μM PMBN-FITC for indicated 
time points in different media. Data are represented as mean + SD (n = 3). 
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phase due to their reliance on processes related to cell growth and division. Therefore, 
PMBN derivatives have heightened potential to act as an immunotherapeutic towards 
hard to treat bacterial infections.   
 
 
 
 
 
 
 
Figure 4.9 DIC and Fluorescent Microscopy Image of PMBN-FITC Labeled 
E. coli.  Stationary phase E. coli were incubated in LB supplemented with 40 μM 
PMBN-FITC for 2 h at 37 °C. Cells were washed and imaged. Scale bar represents 2 
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4.3.2 PMBN-DNP Mediated Opsonization of E. coli  
The outer membrane (OM) of Gram-negative bacteria (Figure 4.10) is a unique 
and highly asymmetric lipid bilayer, heavily populated by proteins and other 
biopolymers. Composed of phospholipids in the inner leaflet and lipopolysaccharide 
(LPS) in the outer leaflet, the complexity and crowdedness of the OM makes it an 
effective barrier against the permeation of both hydrophobic and hydrophilic compounds. 
LPS, a complex amphiphatic molecule, consists of lipid A, a core oligosaccharide, and an 
O-antigen polysaccharide. The O-antigen varies in length depending to the bacteria and is 
comprised of oligosaccharide. It also renders additional protection from the antimicrobial 
action of certain antibiotics and can potentially interfere with the approach and binding of 
extracellular antibodies onto haptens.19 
 
 
 
 
 
 
 
 
 
 
Figure 4.10 Gram-negative bacterial Outer Membrane Molecular Complexity. 
The LPS molecule can be divided into three main regions: Lipid A, which anchors 
LPS to the outer membrane, the core region, containing the majority of the 
functional groups, and the repeating O-antigen unit. (Left) Chemical structure of 
endotoxin from E. coli O111:B4 according to Ohno and Morrison.2  
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We hypothesized that the accessibility of DNP epitopes to the extracellular space 
could drastically effect antibody recruitment to the bacteria surface and therefore reduce 
immune response. Furthermore, the OMs of bacteria strains vary, in regards to the 
makeup of the O-antigen. We anticipated that the structure and dynamics of the 
conjugates would impact the interactions of PMB and LPS, exposure of DNP to the outer 
space, and the stability of the OMs. In designing the PMBN-DNP conjugate that could 
recruit endogenous antibodies, the PMBN and DNP units cannot be altered. Modification 
of those chemical structures can lead to poor surface homing and/or poor antibody 
recruitment.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11 Structures of Polymyxin B 
and PMBN-DNP conjugates with PEG 
linkers.  
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However, the linker connecting the two units must be carefully designed to: (1) 
minimally disrupt the binding to LPS on bacterial cell surface (PMBN), (2) maximize 
DNP availability on cell surfaces, and (3) possess the proper chemo-physical properties 
of a drug-like molecule.  
We chose the flexible spacer, polyethylene glycol (PEG), to be coupled onto the 
N-terminus followed by the arylation with DNP (Figure 4.11). We reasoned that the PEG 
spacer may play a pivotal role in determining antibody recruitment levels by improving 
the hapten presentation. In collaboration with the Regen Group, they synthesized a 
fragment of PMB known as PMB nonapeptide (PMBN) (Figure 4.11). PMBN is devoid 
of the membrane-disrupting fatty acid tail but, critically, retains the cyclic heptapeptide 
responsible for association to Lipid A.11, 10 The smaller PMBN fragment has attenuated 
antimicrobial activity, which can be useful in isolating the effect of surface-homing in our 
strategy. Therefore, we synthesized, purified, and characterized 7 PMBN- (PEG) 2-24-
DNP conjugates, which systematically varied on the number of PEG units (Scheme 4.2, 
Scheme 4.3).   
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Scheme 4.2 Synthesis of PMBN-PEGx-DNP Conjugates. (BOC)-PMBN (1eq.) was 
reacted with PEG2-DNP (1.5eq.) in DMF with HATU (1.4eq.) and DIEA (3eq.). After 
reaction time, the product was extracted with DCM and the protecting groups were 
removed in acidic conditions. Purification on normal phase with 2% MeOH / DCM 
afforded conjugate, PMBN-PEG2-DNP. Synthesis was repeated for conjugates with 
PEGx (x = 4, 6, 12). 
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Scheme 4.3 Synthesis of PMBN-PEGx-DNP Conjugates. Amino-PEG16-acid (1eq.) 
was reacted with 2, 4-dinitrofluorobenzene (5 eq.) in a mixture of MeCN and NaHCO3 
for 2 h. After extraction with DCM, the product was isolated and used without further 
purification. (BOC)-PMBN (1 eq.) was reacted with PEG16-DNP (1.5eq.) in DMF with 
HATU (1.4eq.) and DIEA (3eq.). After reaction time, the product was extracted with 
DCM and the protecting groups were removed in acidic conditions. Purification on 
normal phase with 2% MeOH / DCM afforded conjugate, PMBN-PEG16-DNP. 
Synthesis was repeated for conjugates with PEGx (x = 20, 24).
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We continued our investigations into this immunotherapy strategy utilizing E. coli 
as the initial model organism to evaluate antibody recruitment. In this experiment, E. coli 
cells from overnight stationary phase (106 cells) were treated with the panel of DNP-
(PEG)2-24-PMBN agents. Following the treatment, E. coli cells were incubated with 0.02 
μg/mL FITC-labeled anti-DNP antibody for 1 h at 37 °C.  After washing and fixing cells 
in 4% formaldehyde, the cells were analyzed for cellular fluorescence by flow cytometry 
(Figure 4.12).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12 PMBN-PEGx-DNP mediated antibody recruitment in E. coli. 
Stationary phase E. coli were incubated in LB supplemented with 40 μM of 
PMBN-PEGx-DNP of varying lengths for 2 h at 37 °C. Incubation with anti-
DNP antibodies followed and cells were analyzed via flow cytometry. Data are 
represented as mean + SD (n = 3).  
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The length dependence observed suggests that there is a particular tether length 
that optimizes hapten presentation by displaying it away from the immediate OM. 
Remarkably PMBN-PEG12-DNP treatment resulted in a robust recruitment of antibodies. 
To the best of our knowledge, this is the first demonstration of a strategy that induces the 
recruitment of antibodies to surfaces of Gram-negative bacteria using small molecules. 
Most importantly, this level of recruitment was observed in bacterial cells from the 
stationary phase.  
Next, we assessed the toxicity of PMBN-PEG12-DNP to E. coli. As PMBN 
displays minimal bacterial toxicity, we expected an attenuated response in cells treated 
with PMBN-PEG12-DNP. As such, we observed low toxicity in E. coli treated with up to 
30 μg /mL of PMBN-PEG12-DNP (Figure 4.13). The MIC was defined as the lowest 
Figure 4.13 PMBN-PEG12-DNP Toxicity towards E. coli. E.coli cells were 
incubated with varying concentrations of PMBN-PEG12-DNP for 18 h at 37 °C. 
Bacterial viability was evaluated by measuring the absorbance at 600 nm. Data are 
represented as mean + SD (n = 3). 
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concentration at which visible bacterial growth was inhibited following 18 h incubation at 
37 °C. For PMBN-PEG12-DNP, 43.95 µg / mL (25 μM) is the MIC in E. coli. Separately, 
high cell density stationary-phase cultures of E. coli were treated with various 
concentrations of PMBN-PEG12-DNP (0, 17.3, 34.6, 69.2, 103.7, 138.3, 172.9 μg /mL or 
10, 20, 40, 60, 80, 100 µM). Time-kill studies were performed at 37 °C with shaking at 
250 rpm. At the indicated times, bacterial aliquots were removed and plated on LB agar 
plates  which were then incubated for 18 h at 37 °C.  Cell viability was assessed by 
enumerating the CFU (colony forming units) per milliliter. It was demonstrated that the 
number of viable cells was reduced quickly by several logs for E. coli treated with 60 µM 
or greater of PMBN-PEG12-DNP (Figure 4.14). Conversely, we observed a slow killing 
effect with E. coli treated with 40 µM of PMBN-PEG12-DNP. 
Figure 4.14 Toxicity of PMBN-PEG12-DNP towards Stationary phase
E. coli. E. coli cells in the stationary phase of growth were treated with 
increasing concentrations of PMBN-PEG12-DNP for indicated times. Cell 
viability was assessed by enumerating colonies from overnight incubation 
on LB agar culture plates. Data displayed as CFU/mL (concentration) over 
time. 
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Killing of Gram-negative bacteria that are in a stationary phase of growth has 
been described as a specific characteristic of the bactericidal action of polymyxin B.20  In 
this study it could be demonstrated that stationary phase E. coli reacts differently to 
PMBN-PEG12-DNP presence, whereas killing curves with logarithmically growing 
bacteria exhibited a lower tolerance to high concentrations to PMBN-PEG12-DNP.  
Next, we set out to assess the toxicity of PMBN-PEG12-DNP against host 
mammalian cells. One concern we had is the overall negative charge of mammalian cells 
and the probability of interacting with positive charged molecules. To evaluate the 
toxicity of PMBN-PEG12-DNP, HEK293 cells were incubated in the presence of varying 
concentrations of PMBN-PEG12-DNP for 72 h and analyzed by standard viability assays 
(Figure 4.15). At all concentrations examined, we observed no significant loss of 
viability. 
 In conclusion the assessment of PMBN-PEG12-DNP toxicity, we show that the 
conjugate is relatively non-toxic (Table 4.1). We determined that the conjugate is non-
toxic to bacterial cells in the growth phase. The MIC of PMBN-PEG12-DNP in E. coli  is 
consistent with the MIC observed for PMBN.21 Thus, the addition of PEG linker and 
DNP moiety does not affect the attenuated toxicity of PMBN. Conversely, we observed a 
high tolerance for PMBN-PEG12-DNP in stationary phase E. coli. This data hints at 
another mechanism of action given the nature of the interaction between PMBN and LPS 
on cell surfaces is independent of cell growth and division.   
 
 
 
105 
 
 
 
 
Figure 4.15 PMBN-PEG12-DNP Induced Mammalian Cell Toxicity. HEK293 cells 
were incubated for 72 hours in the absence or the presence of increasing concentrations 
of PMBN-PEG12-DNP. Cellular viability was evaluated with MTT by measuring 
absorbance at 580 nm. Data are represented as mean + SD (n = 3). 
 
Table 4.1 PMBN-PEG12-DNP Toxicity towards E. coli and Mammalian Cells. 
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4.3.3 PMBN-DNP Potentiation of Antibiotics 
Studies have been carried out showing that the addition of PMBN renders Gram-
negative bacteria susceptible to several antibiotics by permeabilizing their outer 
membranes.22, 23 Given the ability of PMBN to potentiate large-molecular-weight 
antibiotics, we reasoned that PMBN-PEG12-DNP would also act as an antibiotic adjuvant 
capable of sensitizing Gram-negative bacteria to antibiotics typically restricted to Gram-
positive bacteria.  
To test this, we grew E. coli in the presence of increasing concentrations of 
rifampicin accompanied with PMBN-PEG12-DNP at 0.5×MIC. Rifampicin is a 
polyketide antibiotic, which inhibits RNA synthesis. We observed that PMBN-PEG12-
DNP potentiated the activity of rifampicin against E.coli at 37 °C (Figure 4.16). 
Specifically, PMBN-PEG12-DNP synergized with rifampicin (fractional inhibitory 
concentration (FIC) index of ≤0.5), which is hydrophobic, but not with the hydrophilic 
glycopeptide vancomycin (Table 4.2). These data are consistent with antibiotic 
potentiation by PMBN, where synergy with hydrophobic molecules is generally more 
pronounced than that with hydrophilic molecules.22 
 
 
 
 
Table 4.2 Evidence of Synergy against E. coli. Fractional inhibitory concentration (FIC) 
indices were calculated against E. coli using microdilution assays with maximum 
concentrations of PMBN-PEG12-DNP at 25 μg/mL, and drugs, rifampicin and 
vancomycin, set to 50 µg/mL and 100 µg/mL, respectively. MICD is the minimum 
inhibitory concentration of each drug alone. MICP is the MIC of PMBN-PEG12-DNP 
alone. FICD is the FIC of each drug. FICP is the FIC of PMBN-PEG12-DNP. FICx = 
[x]/MICx, where [x] is the lowest inhibitory concentration of drug in the presence of co-
drug, and MICx is the MIC of x in the absence of co-drug. 
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A 
B 
Figure 4.16 Potentiation of Antibiotics. E. coli toxicity of rifampicin (A) and vancomycin 
(B) in the presence of 12.5μM (0.5×MIC) PMBN-PEG12-DNP for 18 h at 37 °C. Bacterial 
viability was evaluated by measuring the absorbance at 600 nm. Data are represented as 
mean + SD (n = 3). 
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4.3.4 PMBN-DNP Mediated Opsonization of P. aeruginosa   
Next, we set out to determine if this strategy was compatible in other pathogenic 
Gram-negative bacteria. We chose to study Klebsiella pneumoniae, Acinetobacter 
baumannii, and Pseudomonas aeruginosa. As seen in Chapter 1, therapies for these 
bacteria are among those listed in the World Health Organization’s account of critical 
priority. Although the strains used in this study were non-resistant strains, the feasibility 
of this strategy towards these bacteria will serve as a proof-of-principle in targeting more 
dangerous bacterial strains.  
As previously mentioned, the conserved domains of the LPS are shared regions 
among bacterial species, which intervene in the development and in the survival of the 
bacteria. The O-antigen may display modifications, such as alterations in the length of the 
oligosaccharide chain, changes in the surface composition, and changes in the chemical 
configuration the O-antigen of Gram-negative bacteria.24 It also renders additional 
protection from the antimicrobial action of certain antibiotics and participates in the 
inhibition of the membrane attack complex (MAC) during an immune response.25  
Up until this point, we were using an E.coli strain (K12) devoid of the O-antigen 
layer for assessing antibody recruitment (Figure 4.17). Acting as a model system, the K12 
strain displayed pronounced antibody recruitment with our synthesized panel of PMBN-
DNP conjugates. In order to determine the usefulness of this strategy against clinically 
relevant bacterial strains, we assessed antibody recruitment in Klebsiella pneumoniae, 
Acinetobacter baumannii, and Pseudomonas aeruginosa.  
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Figure 4.17 Schematic Representation of Variety in Lipopolysaccharide 
Structures. Gram-negative bacteria can have varying designs of LPS, which 
represents 75% of the total surface. There is smooth-type (left), which contains 
a strain specific O-antigen that varies in length. The bacterial surface can also 
be of the semi-rough type with only one O-chain subunit (center) and rough-
type (right), which halts LPS biosynthesis at the inner saccharide core.1 
(Mechanisms of O-Antigen Structural Variation of Bacterial Lipopolysaccharide 
(LPS), Reyes, R. E, 2012, Ch.3.) 
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We incubated each strain with 40 μM of PMBN-PEGx-DNP, where x = 12, 16, 
20, 24, for 2 h during the stationary phase lifecycle for the bacteria.  We did not observe 
any recruitment capability for any of conjugates in Klebsiella pneumoniae or 
Acinetobacter baumannii. However, we observed roughly an 8-fold increase in 
fluorescence in Pseudomonas aeruginosa treated with PMBN-PEG12-DNP over the other 
conjugate-treated and untreated bacteria (Figure 4.18). This is, to our knowledge, the first 
synthetic conjugate capable of facilitating endogenous antibody recruitment to a 
pathogenic Gram-negative organism.  
Figure 4.18 PMBN-PEGx-DNP mediated antibody recruitment in 
Pseudomonas aeruginosa. Stationary phase Pseudomonas aeruginosa were 
incubated in LB supplemented with 40 μM of PMBN-PEGx-DNP of varying 
lengths for 2 h at 37 °C. Incubation with anti-DNP antibodies followed and 
cells were analyzed via flow cytometry. Data are represented as mean + SD 
(n = 3).  
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Due to the complexity related to LPS, we have a limited molecular-level 
understanding of how the bacterial outer membranes behave for various types of bacteria. 
Therefore, we have collaborated with the Im laboratory at Lehigh University, who 
developed a unique technique to build and simulate complex outer membranes of Gram-
negative bacteria, including different cores and O-antigens of E. coli and P. aeruginosa. 
In attaining this information, we will look forward to the de novo design of linkers to 
achieve high levels of surface labeling and proper display of antigens for antibody 
recruitment, specific for the surface of the bacteria we aim to target.  
 
 
 
 
 
 
 
 
 
 
 
 
 
112 
 
4.3.5 Induced Toxicity with Fatty Acid Derivative  
We expected that the re-introduction of the fatty acid tail will improve the 
inherent antimicrobial activity of the conjugates. More importantly, antibody recruitment 
will be expected to be efficient at lower concentrations. The ability of the fatty acid tail to 
imbed within the outer membrane should result in better affinity towards Lipid A and 
longer residency time of the entire construct onto the bacterial cell surface.  
We synthesized an octanoic acid derivative via solid-phase peptide synthesis 
(Scheme 4.4). Chlorotrityl resin was loaded with N-α-Fmoc-N-ε-4-methyltrityl-L-lysine 
(Fmoc-L-Lys(Mtt)-OH). The N-terminus of lysine was deprotected to allow for the 
coupling of caprylic acid (octanoic acid). Selective unmasking of the Nε-methyltrityl 
protecting group was completed in mild acidic conditions. The free amine was then 
reacted with Fmoc-N-amido-PEG12-acid in the presence of coupling agent and base. 
Deprotection of the construct, followed by conjugation of 2, 4-dinitrofluorobenzene 
allowed for the completion of portion of the construct on solid support. The construct was 
cleaved from the resin and reacted with (BOC)PMBN. After reaction time and removal of 
BOC protecting groups, the final construct was purified on RP-HPLC and characterized 
by MALDI-TOF MS. 
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Scheme 4.4 Synthesis of PMBN-PEG12-DNP(Oct). Peptide construct was built via 
solid-phase peptide synthesis as previously discussed. Construct was reacted with 
(BOC)PMBN. Protecting group removal and purification, afforded the final 
derivative.  
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We assessed the toxicity of PMBN-PEG12-DNP(Oct) to E. coli. We expected this 
conjugate to replace the inherent antimicrobial activity of the conjugates. As such, we 
observed high toxicity in E. coli treated with concentrations as low at 5 μg /mL of 
PMBN-PEG12- DNP(Oct) (Figure 4.12). The MIC was defined as the lowest 
concentration at which visible bacterial growth was inhibited following 18 h incubation at 
37 °C. For PMBN-PEG12- DNP(Oct), 3.09 µg / mL (1.56 μM) is the MIC in E. coli. 
 
 
 
 
Figure 4.19 PMBN-PEG12-DNP(Oct) Toxicity towards E. coli.  
E.coli cells were incubated with varying concentrations of PMBN-PEG12-DNP 
octanoic acid for 18 h at 37 °C. Bacterial viability was evaluated by measuring 
the absorbance at 600 nm. Data are represented as mean + SD (n = 3). 
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4.3.6 Pooled Human Serum Bacterial Cell Opsonization 
Next, we set out to investigate the ability of the conjugates to induce opsonization 
in a physiologically-relevant environment. Up to this point, we have shown that by 
associating the the bacterial surface, PMBN-PEGx-DNP conjugates can trigger the 
recruitment of purified FITC-labeled anti-DNP IgG antibodies. While these results 
establish the feasibility of the overall strategy, the recruitment of IgG antibodies in a 
human host would have to be derived directly from the serum. The recruitment of serum-
associated IgG antibodies could potentially fail due to interference with serum proteins, 
lack of specificity, and overall lack of anti-DNP abundance. Therefore, it was critical to 
evaluate this strategy in the biologically relevant conditions. The lack of a fluorescent 
handle on IgG antibodies from the pooled human serum necessitated the introduction of a 
secondary antibody. 
 
 
Figure 4.20 Cartoon Representation of Antibody Recruitment using Pooled Human 
Serum.  
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In this assay, IgG antibodies from pooled human serum that had opsonized the 
bacteria cell surface were detected using a FITC-labeled anti-human IgG antibody via 
flow cytometry (Figure 4.20). We chose to assess the recruitment capability of PMBN-
PEG12-DNP octanoic acid for this assay. As this conjugate displays acute toxicity to 
E.coli, the potential of this conjugate to possess dual- modes of thwarting bacterial cells 
was exciting.  
We observed that in the absence of pooled human serum, there was slight cell-
associated fluorescence signal from untreated E. coli cells. These results indicated that 
there is non-specific binding of the FITC-labeled anti-human antibody on the surface of 
E. coli cells. Upon treatment with 25% pooled human serum to cells treated with PMBN-
PEG12-DNP(Oct) led to an increase in fluorescence signal (Figure 4.21). There was a 3-
fold increase in cell-associated fluorescence for cells incubated with the conjugate of 1 h. 
This data points to this strategy being compatible with conditions that mimic the human 
host environment.  
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Figure 4.21 Antibody Recruitment from Pooled Human Serum in E. coli.  
E.coli cells were incubated with 20 μM of PMBN-PEG12-DNP(Oct) for indicated 
time points at 37 °C. Cells were subsequently incubated with either 25% pooled 
human serum or PBS, followed by the incubation with FITC-labeled anti-human 
IgG antibodies and analyzed using flow cytometry. Data are represented as mean + 
SD (n = 3).  
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4.4 FUTURE WORK 
We have developed a series of conjugates capable of facilitatating the recruitment 
of endogenous antibodies to the surface of Gram-negative bacteria. As mentioned, we are 
lacking in our ability to fully understand the on-goings of the outer membrane. Our 
current collaboration with the Im laboratory will hopefully illuminate key structural 
differences among the bacteria surfaces, in order to rationally design more effacioucs 
immune attractant molecules.  
In generating a more robust immune repsonse, we have synthesized a PMBN 
connstruct displaying the rhamnose antigen in place of the DNP epitope. It has been 
recently shown there is a greater abundance of endogenous anti-rhamnose antibodies 
compared to anti-DNP antibodies in human serum.26, 27 Therefore, the switch to 
rhamnose antigens should result in even higher levels of antibody recruitment due to the 
higher abundance of anti-rhamnose in human serum. As we have shown the recruitment 
of antibodies directly from pooled human serum, we can apply this assay to evaluate the 
PMBN-rhamnose constructs, as anti-rhamnose antibodies are not commercially available. 
Additionally, anti-rhamnose opsonization can induce more effective pathogen killing.27 If 
successful in facilitating the recruitment of anti-rhamnose antibodies from pooled human 
serum, the opsonized pathogens will be targeted for complement-dependent cytotoxicity 
(CDC) or antibody-dependent cell-mediated cytotoxicity (ADCC). By elevating the 
levels of antibodies on the surface of bacteria, we expect to see an induction in bacterial 
lysis by the serum-components and directly by human immune cells. 
 
 
119 
 
4.5 CONCLUSION 
In this immunotherapy strategy, we utilized the homing properties of polymyxin 
B to design polymyxin B nonapeptide-antigen conjugates capable of inducing the 
recruitment of antibodies to the surface of Gram-negative bacteria. We show that PMBN-
FITC targets Gram-negative E. coli and maintains assosciation with the abcterial surface 
through ionic interactions with the negatively charged E. coli surface. From these data, 
the possibility of PMBN-antigen conjugates interacting with the surface long enough to 
facilitate the recruitment of antibodies was conceivable. Therefore, we synthesized a 
panel of PMBN-antigen conjugates, employing a PEG spacer and DNP antigen. Our 
results demonstrate that PMBN-PEGx-DNP induce the recruitment of anti-DNP 
antibodies to the surface of E. coli. We hypothesize that spacer length requirement arise 
from differences in complexity of the LPS on the bacterial surface. We identified that 
PMBN-PEG12-DNP is the optimal construct for efficient recruitment in E. coli and P. 
aeruginosa. Further studies need to be conducted in order to answer fundamental 
questions and may be achieved by computational simulations of outer membrane 
behavior.  
Furthermore, we show that PMBN-PEG12-DNP potentiates the activity of the 
hydrophobic antibiotic, rifampicin. Similar to PMBN, this construct displays minimal 
toxicity to E. coli and mammalian cells. We also show that re-introduction of the fatty 
acid tail eccentuates the toxicity of the construct to E. coli. This is an important feature 
that can be tailored based on the level of toxicity desired for studying dual-mode 
approahces to combatting Gram-negative bacteria. Finally, we show that our conjugate 
can tigger the recruitment of anti-DNP antibodies directly from pooled human serum. 
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Further investigations into this strategy, may prove great potential to be an effective 
therapy against bacterial infections caused by challenging Gram-negative pathogens. 
Although, there have been extreme cases where bacteria have evolved their LPS, 
resistance to polymyxin B is rare.28, 29 We plan to explore the ability of these conjugates 
to label E. coli bacterial in the future by using live organism models. We anticipate that 
these agents will be excellent lead compounds as a bacterial immunotherapy strategy 
against Gram-negative pathogenic bacteria. 
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Chapter 5 
Fluorescence-based Assay Monitors PAD2 and PAD4 Activity 
 
5.1 ABSTRACT  
Post-translational modifications (PTMs) can greatly increase the functional diversity 
of the modified protein by changing its size, charge, and/or structure. As a result, PTMs 
may lead to physiological consequences. Peptidylarginine deiminases (PADs) are a 
family of post-translational modifiers which catalyze the calcium-dependent conversion 
of arginine residues to non-tRNA encoded citrulline residues. The full extent of the role 
PADs play in normal physiology and diseased states is not yet fully understood, however 
in some diseases, such as rheumatoid arthritis, a clear correlation between arginine 
citrullination and manifestation of the disease exists. Although this correlation is known, 
few assays described to date have been operationally facile with satisfactory sensitivity. 
This chapter explores a new, facile, fluorescence-based assay that reports on the activity 
and inhibition of two isoforms of the PAD family: PAD2 and PAD4.  The data, herein, 
show the assay to be readily performed under ambient conditions displaying a high signal 
to noise ratio. Furthermore, through collaboration with Penn State Hershey Medical 
Center, we utilized the assay in a high-throughput screen for potential PAD4 inhibitors.   
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5.2 INTRODUCTION  
5.2.1 Post-Translational Modifications  
Within any particular cell, there exists a delicate balance among protein expression, 
modification, and degradation, all of which are crucial in maintaining cellular 
homeostasis. Modifications that are made to proteins after ribosomal biosynthesis are 
called post-translational modifications (PTMs). These post-translational modifications 
(PTMs) can greatly increase the functional diversity of the modified protein by changing 
its size, charge, structure, and oligomerization state, amongst other features.1, 2, 3 As a 
result, the change in protein structure can lead to physiological consequences, such as 
protein degradation, cellular differentiation, signaling, modulation in gene expression, 
and protein-protein interactions. While these modifications are prevalent in a large 
percentage of all human proteins, the terminal ends on histone proteins undergo an 
unusually high number of covalent modifications.4  
Histone proteins are a family of structural proteins that facilitate the condensation of 
genomic DNA. Covalent modifications of the unstructured histone tails are carried out 
and regulated by a series of enzymes that can catalyze the covalent modification of 
residues (writers), reverse the same modifications (erasers), and distinguish among the 
changes being imprinted onto the histone tails (readers).5, 6, 7 In fact, most of the known 
PTMs can be observed within this short segment of the histone including methylation, 
phosphorylation, acetylation, sumoylation, ubiquitination, and citrullination.8. 
Within the past decade, the identification and characterization of post-translational 
modifications (PTMs) have received a significant amount of research interest9. The vast 
and versatile protein products generated by PTMs allow for the diversification of proteins 
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potentially influencing both normal cellular homeostasis and diseased states. A 
dysregulation in PTMs can lead to proteins with altered or expired functions. While most 
PTMs are fully reversible, a few appear to permanently alter the protein structure.  
5.2.2 Peptidylarginine Deiminases 
Peptidylarginine deiminases (PADs) catalyze the post-translational conversion of 
arginine residues to the non-tRNA encoded citrulline residues in the presence of calcium. 
The full extent of the role PADs play in diseased states is not yet fully established, yet 
rheumatoid arthritis patients harbor an elevated level of citrullinated proteins.10, 11, 12 
Aberrant protein citrullination has also been found to be elevated in multiple sclerosis 
(MS)13, Alzheimer’s disease14, lupus15, and various types of cancer16, 17, thus suggesting a 
possible intervention pathway via therapeutics. Amid the five PAD isoforms, PAD2 and 
PAD4 are commonly overexpressed in the aforementioned diseases.  
Assays that readily and reliably measure the activity of PAD2 / PAD4 would not only 
enhance our understanding of PADs, but also aid in the search for potent and specific 
inhibitors. To date, five members of the PAD family have been described (PAD1, PAD2, 
PAD3, PAD4, and PAD6). Each member of this family appears to target distinct cellular 
proteins and displays unique tissue distribution profiles.  PAD4 is the only member of 
this protein family known to be localized within the nucleus via a nuclear localization 
sequence.18 Accordingly, it has been shown to deiminate a number of nuclear targets, 
including arginine side chains on the N-terminal tails of histones H2A arginine residue 3 
(H2R3), H3 (H3R2, H3R17, and H3R26) and H4 (H4R3)19,20. While each of the PAD 
isozymes have specific and critical physiological functions, PAD4 has received 
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considerably more attention due to its role in a number of human processes in both 
diseased and healthy cells. Recently, PAD4 was shown to be a member of the 
pluripotency transcriptional network21.  In a recent experiment, PAD4 expression levels 
and activity were shown to be elevated during reprogramming and ground-state 
pluripotent states in mice. By controlling the regulation of stem-cell genes, PAD4 may 
retain a pivotal role in cellular reprogramming efficiency. PAD4 has also been implicated 
in the formation of neutrophil extracellular traps, which upon binding of pathogens 
enable their system clearance. The hypercitrullination of histone proteins by PAD4 
induces decondensation of the chromatin, which serves as the base material for the 
encapsulation of pathogenic bacteria by the extracellular trap, thus warding off bacterial 
infections22.  
PAD2 is widely expressed in the brain, secretory glands, and skeletal muscles. 
PAD2 overexpression is responsible for hypercitrullination of myelin basic protein 
(MBP), which leads to myelin sheath integrity loss in multiple sclerosis23. Recently, the 
overexpression of PAD2 in cell carcinoma cells led to an elevated tumorigenic profile, 
including markers consistent with epithelial-to-mesenchymal transition (EMT)24. The 
same study found that the overexpression of PAD2 in transgenic mice induced 
spontaneous skin lesions, which also showed high EMT and invasion markers.  
The use of small molecules to turn off the function of PADs may prove to be a 
powerful new strategy in thwarting the consequences due to aberrant protein expression. 
Toward this end, several activity assays have been developed with the goal of discovering 
new PAD inhibitors. A number of covalent inhibitors have been developed by the 
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Thompson group using the chloro/fluoro imidine handle that mimics the arginine 
substrate25,26,27 and have proven to be practical tools in understanding the role of PAD4 in 
both healthy and diseased state cells. PAD4 assays have also been described that link the 
release of ammonia from the reaction to a colorimetric readout28, utilize a fluorescently 
labeled chloroamidine substrate analog for fluorescence polarization assay,29 rely on the 
acid-assisted reaction between glyoxal and citrulline30, and couple the PAD4 activity to a 
fluorescence dequenching step31. Of these, only the covalent modifier haloacetamidine 
strategy has been proven to be compatible with high-throughput screening platforms32 
and few are operationally facile with satisfactory sensitivity. The lack of adequate assays 
has likely contributed to the absence of potent non-covalent PAD4 inhibitors. 
Here, we describe a new mechanism-based fluorescence assay that quickly and 
reliably measures the activity of PAD2 / PAD4. We reason that we could monitor PAD2 / 
PAD4 activity by utilizing the pro-fluorescent substrate analog. When acting upon 
substrate histones 3 and 4, PAD4 converts a positively charged arginine side chain to a 
neutral side chain through the citrullination reaction, which is currently thought to be 
irreversible (Figure 5.1). The neutralization of this positive charge has important 
implications for the association of histones with the negatively charged genomic DNA, 
potentially modulating transcriptional regulation and promoting the formation of 
neutrophil extracellular traps (NETs).33 The citrullination of arginine could similarly be 
leveraged to monitor PAD4 activity. Furthermore, citrullination of arginine would also 
interfere with the ability of trypsin to hydrolyze the carboxyl side of the amide bond. 
Trypsin has a distinct preference in hydrolyzing the C-terminal amide bonds of both 
lysine and arginine, with optimal activity near a pH range of 7.5 to 8.5. 
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 The incorporation of a masked fluorophore (7-amino-4-methylcoumarin, AMC) on 
the carboxyl side of arginine could be used to generate a signal upon trypsin-mediated 
hydrolysis. Acylation of AMC is known to greatly reduce its fluorescence intensity, a 
feature that has been utilized in a number of protease assays.34 Likewise, acylation of 
AMC onto the arginine is expected to greatly reduce the fluorescence of the potential 
PAD4 substrate (Scheme 5.1). In addition, a carboxybenzyl (Cbz, Z) group on the amino 
side of the arginine was included to mimic the typical protein-based substrate of PAD4. 
The N-terminus acetylation was crucial since it has been previously reported that neither 
free arginine nor arginine-methyl ester is citrullinated by PAD4 to any appreciable 
levels20.  
As shown by Wildemen et al., the modification of arginine with the unnatural 
moieties AMC and Cbz is well-tolerated in the active site of PAD4 and responds to 
trypsin-mediated hydrolysis.35 The substrate, ZRCoum, was also shown to efficiently 
convert to the expected product upon co-incubation with PAD4.35 In furthering the initial 
framework of this design, we set up to optimize the assay for high-throughput screening 
platforms and extend the assay to other PAD isoforms.  
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Scheme 5.1 PAD Assay Design. (A) A schematic representation of the octameric 
histones found in a basic unit of a nucleosome. PAD4 is able to citrullinate a number 
of arginine residues on histone proteins. (B) Schematic representation of the PAD 
assay. The citrullination reaction catalyzed by PAD renders the substrate (ZRCoum) 
resistant to trypsin-mediated amide hydrolysis, thus leading to a change in fluorescence 
levels. 
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5.3 MATERIALS AND METHODS 
5.3.1 Materials 
The PAD2 – GST and PAD4 – GST fusions containing pGEX-6P plasmid were a 
kind gift from Dr. Yanming Wang and Dr. Walter Fast, respectively. Luria Broth (LB), 
Isopropyl-β-D-thiogalactopyranoside (IPTG) and Ampicillin trihydrate were purchased 
from Sigma Aldrich. LB Agar, Miller granulated was purchased from Fisher Scientific. 
Z-Arg-L-7-amino-4-methylcoumarin, 7-amino-4-methylcoumarin, benzamidine, and 
phenylmethylsulfonyl fluoride (PMSF) were purchased from Sigma Aldrich. Cl-amidine, 
PAD inhibitor, was purchased from Chem Impex. Compound YW4-03 was supplied by 
Yanming Wang. Trypsin, crystalline from Bovine Pancreas (Amresco) was purchased 
from Sigma Aldrich. All salts were purchased from Fisher Scientific.  
5.3.2 PAD2 / PAD4 Expression and Purification 
The PAD2 – GST / PAD4 – GST fusion containing pGEX-6P plasmid were 
transformed into chemically competent Escherichia coli BL21(DE3) cells. The cells were 
plated on an ampicillin-containing agar-LB plate and incubated overnight at 37 °C. A 
single colony was picked and grown overnight in 50 mL of lysogeny broth (LB) 
containing 1 mM ampicillin at 37 °C. LB (8 L) containing 1 mM ampicillin was 
inoculated with the overnight growth medium. Cells grew to an OD = ~0.2, when they 
were moved to a 16 °C environment and continued to OD = ~0.6. Protein production was 
induced with 0.3 mM isopropyl-β-D-thiogalactopyranoside and incubated overnight at 16 
°C while shaking at 250 RPM. Cells were harvested by centrifugation at 3, 500 x g for 30 
min at 4 °C. The remaining cell pellet was resuspended in 100 mL lysis buffer containing 
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50 mM NaH2PO4, 300 mM NaCl, 10 mM Imidazole, 1 mM PMSF, and 1 mM DTT. The 
mixture was sonicated for 15 min and centrifuged at 20,000 x g’s for 30 min at 4 °C. The 
transparent supernatant was transferred to a Protino’s glutathione agarose 4B column. 
After washing steps with 1 X PBS (3 × 10 mL per mL of bead volume) the protein was 
eluted with 10 mL elution buffer (50 mM Tris HCl, 10 mM glutathione, pH = 8.0). The 
eluent was further purified and concentrated by using a 100 MWCO spin column. SDS-
PAGE was utilized to verify the expected molecular weight and purity of the protein. 
Aliquots were stored in –80 °C. 
5.3.3 PAD Activity Assay  
GST-tagged PAD2 or PAD4 was introduced to reaction buffer with a final 
concentration of 50 mM tris(hydroxymethyl)aminomethane hydrochloride (Tris HCl), 50 
mM NaCl, 1 mM tris(2-carboxyethyl)phosphine (TCEP) and 10 mM CaCl2 (pH = 8.0) 
and incubated for 10 min at 37 °C. ZRCoum (25 μM) was added to the wells and the 
reaction continued for 2 h at 37 °C. Quenching of the reaction occurred upon the addition 
of 10 μL 10 mg/mL trypsin/100 mM EDTA. After 10 min, fluorescence values were 
obtained via Tecan Infinite 200 (λex = 340nm, λem = 475nm).  . 
5.3.4 Calcium Dependence Analysis 
GST-tagged PAD2 or PAD4 was incubated for 10 min at 37 °C in reaction buffer 
with a final concentration of 50 mM Tris HCl, 50 mM NaCl, 1 mM TCEP and varying 
concentrations of calcium chloride (0 – 10 mM) (pH = 8.0). ZRCoum (25 μM) was added 
and the reaction continued for 2 h at 37 °C. Quenching of the reaction occurred upon the 
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addition of 10 μL 10 mg/mL trypsin/100 mM EDTA. After 10 min, fluorescence values 
were obtained via Tecan Infinite 200 (λex = 340nm, λem = 475nm).  
5.3.5 Kinetic Analysis 
GST-tagged PAD2 / PAD4 was incubated for 10 min at 37 °C in reaction buffer 
with a final concentration of 50 mM Tris HCl, 50 mM NaCl, 1 mM TCEP and 10 mM 
CaCl2 (pH = 8.0). ZRCoum (25 μM, 100 μM, 250 μM, 500 μM, 800 μM and 1 mM) was 
added to specific wells and the reaction was quenched at time points (15, 30, 45, 90, 120, 
and 180 min) by the addition of 10 μL 10 mg/mL trypsin/100 mM EDTA. After 10 min, 
the fluorescence values were obtained via Tecan Infinite 200 (λex = 340nm, λem = 
475nm). The slopes of the data points that displayed a linear relationship of fluorescence 
plotted against time (min) were the values of V0 (µmol / min). From this data, the kinetic 
parameters, kcat and KM, were calculated. 
5.3.6 Trypsin Inhibition Analysis 
PMSF or benzamidine (0 – 1 mM) was introduced to wells containing 25 µM 
ZRCoum for 10 min at 37 °C (Buffer: 50 mM Tris-HCl, 50 mM NaCl, 1 mM TCEP and 
10 mM CaCl2). Quenching of the reaction occurred upon the addition of 10 μL 10 mg/mL 
trypsin/100 mM EDTA. After 10 min, fluorescence values were obtained via Tecan 
Infinite 200 (λex = 340nm, λem = 475nm). 
5.3.7 Small Molecule Inhibition Curves 
GST-tagged PAD2 or PAD4 was incubated for 10 min at 37 °C in reaction buffer 
with a final concentration of 50 mM Tris HCl, 50 mM NaCl, 1 mM TCEP and 10 mM 
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CaCl2 (pH = 8.0). Varying concentrations of inhibitor (0 μM – 100 μM) was introduced 
to the wells for 1 h at 37 °C. ZRCoum (25 μM) was added to the wells and the reaction 
continued for 6 h at 37 °C. Quenching of the reaction occurred upon the addition of 10 
μL 10 mg/mL trypsin/100 mM EDTA. After 10 min, fluorescence values were obtained 
via Tecan Infinite 200 (λex = 340nm, λem = 475nm).  IC50 values were calculated.   
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5.4 RESULTS AND DISCUSSION 
5.4.1 Assay reports on PAD2 / PAD4 Activity  
We set out to determine the suitability of our assay for reporting on the enzymatic 
activity of PAD2 / PAD4 in 96-well plates to demonstrate its potential utility for high-
throughput screening methods.  Reaction wells were incubated with the substrate, 
ZRCoum, in the presence and absence of PAD2 / PAD4. The wells were incubated at 
37°C for 1 h. Next, an excess of trypsin/EDTA was added to designated wells and the 
reaction continued for an additional 10 minutes at 37 °C.  
 
 
Figure 5.1 Fluorescence assay reports on Activity of PAD2 and PAD4. PAD 2 / PAD4 
was incubated in reaction buffer (pH=8.0) with ZRCoum (25µM) at 37 ºC. Fluorescence was 
measured (λex = 340 nm, λem = 475 nm) in the absence (blue) and presence (red) of 
trypsin/EDTA. Data represented as mean +/- SD. 
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Upon treatment with trypsin, the fluorophore, AMC, is uncoupled from the molecule, 
thus restoring its fluorescence. We observe a 5- fold increase in fluorescence levels. The 
change in fluorescence can be readily monitored in solution via its maximum excitation 
~440 nm under physiological pH conditions.  The enzymatic activity of PAD2 / PAD4 in 
converting arginine to citrulline should prevent the unmasking of the fluorophore, 
therefore reducing the fluorescence output. 
Conversely, in wells treated with PAD2 / PAD4 and sequential trypsin/EDTA 
addition, low fluorescence levels are observed (Figure 5.1). This low fluorescence is due 
to substrate conversion in the presence of the enzyme, thus no longer retaining specificity 
for trypsin and foregoing hydrolysis of the fluorophore. The addition of EDTA is 
intended to assist in the cessation of the PAD reaction due its ability to chelate the 
essential calcium ions. From these data, we observe a 6.5-fold decrease in fluorescence 
output in the presence of PAD2 and a 5.6-fold decrease in fluorescence output in the 
presence of PAD4. Trypsin release of the fluorophore is complete within 10 minutes and 
further incubation does not increase the fold difference (Figure 5.2).  From this data, it is 
evident that ZRCoum has the potential to be a fast and facile reporter of PAD2 / PAD4 
activity. 
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Next, we examined the effect the presence of calcium has on PAD activity. The 
binding of calcium ions (up to five binding sites have been identified) leads to a re-
structuring of the protein to generate the active site36. In vitro, calcium binding is known 
to cause a conformational change that moves Cys645 and His471 into positions that are 
competent for catalysis.37  
Indeed, as more calcium ions are titrated in a decrease in the fluorescence is 
observed, consistent with the fluorescence signal being linked to citrullination by active 
PAD2 / PAD4 (Figure 5.3).  
Figure 5.2 Trypsin Hydrolysis of ZRCoum. ZRCoum (25µM) or 
AMC (25µM) was incubated in reaction buffer at 37 ºC. Fluorescence 
was measured (λex = 340 nm, λem = 475 nm) after trypsin/EDTA 
addition at designated time intervals. Data represented as mean +/- SD. 
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Conversely, at very low levels of calcium, fluorescence levels are elevated, 
indicating the PAD enzyme is not as active and the pro-fluorescent ZRCoum is released 
upon trypsin hydrolysis. Interestingly, it is evident that PAD4 restores its full catalytic 
activity at lower concentrations of exogenous calcium ions than PAD2. It is conceivable 
that either the calcium binding sites in PAD4 have tighter affinities for the calcium ions 
or the catalytic activity of PAD2 is more strictly associated with full occupation of the 
calcium binding sites.  
Figure 5.3 Calcium Dependence of PAD2 and PAD4. PAD2 / PAD4 was 
incubated in reaction buffer (pH = 8.0) containing varying concentrations (0 – 
10 mM) of calcium chloride followed by ZRCoum (25µM) addition. After 2 h, 
fluorescence was measured in the presence of trypsin/EDTA. Data represented 
as mean +/- SD. 
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5.4.2 Assay Optimization for High-Throughput Screening  
5.4.2.1 Assay Miniaturization at Room Temperature  
Next, we demonstrated the compatibility of our assay with high-throughput 
screening platforms. We were primarily interested in analyzing five reaction variables 
that would be most favorable for screening purposes: (1) the further miniaturization of 
the assay volume, (2) the possibility of performing the assay at room temperature, (3) the 
stability of the protein and buffer mixture prior to completing the assay, (4) the kinetics 
of the assay, and (5) the potential interference of trypsin inhibitors.   
For mid-throughput or high-throughput screening efforts, high-density well plates 
are commonly utilized in small molecule screens. We verified that the assay can be 
performed almost identically in a 384-well plate as compared to a 96-well plate (Figure 
5.4). In further determining the working conditions for the assay in a high-throughput 
format, we sought to investigate whether PAD4 activity can be monitored in a reasonable 
time frame at room temperature. 
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Since not all liquid-handling instruments have a temperature controller, it can 
become cumbersome and costly to have an incubation step at elevated temperature. 
Furthermore, accounting for fluctuation in temperature can be a cause for discrepancy 
between plates and runs.  In order to determine the effect of lower temperatures for the 
assay described here, we performed a similar assay at room temperature. We found that 
the signals were virtually unchanged between 37o C and room temperature (Figure 5.5). 
 
 
Figure 5.4 Assay Monitors PAD4 Activity in 384 – well plate. PAD4 was 
incubated in reaction buffer (pH=8.0) with ZRCoum (25µM) at 37 ºC in a 384-
well plate. Fluorescence was measured (λex = 340 nm, λem = 475 nm) in the 
absence (blue) and presence (red) of trypsin. Data represented as mean +/- SD. 
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5.4.2.2 Reagent Stability 
Next, we evaluated the stability of PAD4 when dissolved in the reaction buffer 
over a prolonged period of time. Realistically, high-throughput screening will require 
reagents to be generally stable for many hours while the instrument is completing the 
screen. Due to short half-lives of certain reagents, it can be quite expensive and time 
consuming to terminate a screen in order to prepare fresh reagents. Depending on the 
assay conditions, it is not unusual for some assays to be incompatible with high-
throughput screening for this very reason. Minding this potential obstruction, we tested 
the stability of PAD4 in the reaction buffer over several hours. 
Figure 5.5 Assay Monitors PAD4 Activity in 384 – well plate at Room 
Temperature. PAD4 was incubated in reaction buffer (pH=8.0) with ZRCoum 
(25µM) at room temperature. Fluorescence was measured (λex = 340 nm, λem = 
475 nm) in the absence (blue) and presence (red) of trypsin. Data represented 
as mean +/- SD. 
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The enzyme was suspended in reaction buffer and left at room temperature in a sealed 
vial covered from light. At indicated time points, an aliquot was removed for testing in 
the PAD4 activity assay.   We observe almost no loss in enzymatic activity throughout 
the time period, thus indicating that the protein is stable even after sitting at room 
temperature for over 15 hours (Figure 5.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6 Analysis of Reagent Stability. PAD4 was incubated in reaction 
buffer (pH=8.0) with ZRCoum (25µM) at room temperature for a time. 
Fluorescence was measured (λex = 340 nm, λem = 475 nm) in the absence 
(blue) and presence (red) of trypsin. Data represented as mean +/- SD. 
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5.4.2.3 Kinetics of Reaction 
To further optimize the assay performance by minimizing the required incubation 
time between PAD2 or PAD4 and the substrate, we analyzed the kinetics of the reaction. 
We monitored PAD4 activity over time both at room temperature and 37o C. As expected, 
it appears that PAD4 is more active at 37o C (consistent with human physiological 
temperature) with the reaction mostly complete by 20 minutes. Satisfyingly, the reaction 
is not strongly affected by the reduction in temperature down to room temperature. The 
reaction proceeds at approximately half the speed as at the elevated temperature and is 
essentially complete 40-45 minutes post initiation (Figure 5.7).  
 
 
 
 
 
 
 
 
 
 
Figure 5.7 Time Course of PAD4 Reaction. PAD4 was incubated in reaction 
buffer (pH=8.0) with ZRCoum (25µM) at 37 ° C (A) and room temperature (B). 
Fluorescence was measured (λex = 340 nm, λem = 475 nm) in the presence of 
trypsin/EDTA. Data represented as mean +/- SD. 
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From the time course analyses, kinetics constants were calculated and the 
parameters (KM = 397 μM, kcat = 2.98 sec-1, kcat / KM = 7400 M-1sec-1) were found to be 
similar to other PAD4 substrates.28  We observed slightly different parameters with 
PAD2 (KM = 260 μM, kcat = 0.51 sec-1, kcat / KM = 1950 M-1sec-1) compared to PAD4 
(Figure 5.8), which is expected considering their inherent differences in substrate 
preferences. These values are also comparable to a similar substrate evaluated with PAD2 
using the ammonia-release colorimetric assay.38 
 
.  
 
 
 
 
 
 
 
 
 
 
Figure 5.8 Kinetics of PAD2 Reaction. (Left) Michaelis−Menten data obtained from 
varying ZRCoum concentration and time to determine rate, V0, as a function of 
ZRCoum concentration. (Right) Lineweaver-Burk plot (double reciprocal plot) of 
PAD2 activity in the presence of varying concentrations of the substrate, ZRCoum. 
 
144 
 
5.4.2.4 Trypsin Inhibition  
In adapting our assay to high-throughput screening platforms, we addressed the 
possibility of a false negative small molecule inhibitor resulting from unintended 
inhibition of trypsin. The assay we developed couples the citrullination reaction by PAD2 
/ PAD4 with the protease action of trypsin. We imagined that large concentrations of 
trypsin would not reduce the signal-to-noise ratio. Furthermore, we anticipated that small 
molecules that could inhibit trypsin would not disrupt the assay given the quantity of 
trypsin present. To test this, we incubated our assay in the presence of trypsin inhibitors. 
Phenylmethylsulfonyl fluoride (PMSF), a known covalent-inhibitor of trypsin, was 
incubated with the reaction mixture prior to trypsin introduction. We observed that co-
incubation of trypsin with PMSF did not alter the fluorescence output within our assay 
conditions. The assay was also tested against benzamidine, a trypsin inhibitor with 
increased water stability (Figure 5.9). These findings are consistent with the amount of 
trypsin added in the unmasking of the fluorophore, which far exceeds the usual amount of 
potential inhibitor being evaluated and should not result in false positive hits. 
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Figure 5.9 Analysis of Trypsin Inhibition. ZRCoum 
(25µM) was incubated in reaction buffer at 37 °C in 
the presence of trypsin inhibitors. After trypsin/EDTA 
addition, the fluorescence was measured (λex = 340 
nm, λem = 475 nm) in the absence (blue) and presence 
(red) of trypsin/EDTA. Data represented as mean +/- 
SD. 
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Having shown that the assay is tolerant to a variety of conditions that are typically 
encountered in small molecule drug discovery efforts, we set out to highlight the 
selectivity of the reaction by performing the reaction in crude whole cell lysates. E. coli 
cells containing the GST-PAD4 expression vector were induced with isopropyl β-D-1-
thiogalactopyranoside (IPTG), similar to the procedure used for the isolation of GST-
PAD4. Following the disruption of the cell membrane via sonication, the cellular debris 
was separated by centrifugation to afford a clarified cell lysate. When the PAD4-
containing cell lysate was submitted to the same assay conditions as the purified GST-
PAD4 assay, the fluorescence signal varied in agreement with the presence of active 
PAD4 in solution. Cell lysates contain a number of biomacromolecules at high 
concentrations that could potentially interfere with the assay (i.e. the activity of PAD4, 
the fluorescent properties of ZRCoum, and the trypsin hydrolysis). We found that the 
assay was functional in crude cell lysates thus indicating a high selectivity in the reaction 
between PAD4 and ZRCoum. To further demonstrate that the signal decrease in the 
presence of crude cell lysates was specific to the presence of active PAD4, we evaluated 
the effect of Cl-amidine, an established PAD4 inhibitor. The addition of Cl-amidine leads 
to a restoration in the fluorescence signal, consistent with the inactivation of PAD4 
(Figure 5.10). Together, we show that the assay can be further simplified by utilizing 
crude cell lysates for the monitoring of PAD4 activity. 
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Figure 5.10 Assay using Crude Cell Lysate as PAD4 Source. ZRCoum (25µM) 
and cell lysate was incubated in reaction buffer at room temperature in a 384-well 
plate. After trypsin/EDTA addition, the fluorescence was measured (λex = 340 nm, 
λem = 475 nm) in the absence (blue) and presence (red) of trypsin/EDTA. Data 
represented as mean +/- SD. 
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5.4.3 Assay Response to known PAD Inhibitors 
Finally, we evaluated the ability of the assay to respond to the presence of known 
inhibitors: Cl-amidine and YW4-03.37, 39 It was found that both of these compounds 
effectively reduce the citrullination reaction by PAD2 / PAD4, consistent with previous 
findings for these compounds (Figure 5.11). The IC50 values for Cl-amidine are 14 µM 
and 19 µM for PAD2 and PAD4, respectively. The IC50 values for YW4-03 are 6 µM and 
14 µM for PAD2 and PAD4, respectively. Furthermore, the data suggests that YW4-03 is 
a more effective inhibitor for PAD2 than PAD4. This slight selectivity in inhibition is 
especially significant in diseases where PAD2 and PAD4 are both overexpressed and 
supports the existence of novel PAD selective inhibitors. 
 
 
 
 
 
 
 
 
 
 
Figure 5.11 Assay Reports on PAD Inhibition. (A) Chemical structures of Cl-
amidine and YW4-03. (B) IC50 curves of Cl-amidine and YW4-03. Conditions: PAD2 
/ PAD4 (2µM) were incubated with ZRCoum (25 μM) in 384-well plate at 37° C for 6 
h. Fluorescence was measured (λex = 340 nm, λem = 475 nm) in the presence of 
trypsin/EDTA. Data represented as mean +/- SD. 
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5.5 CONCLUSION 
We report a novel rapid and facile fluorescence-based assay of PAD2 / PAD4, 
which relies on the re-design of an arginine substrate. In particular, we incorporated a 
fluorescent moiety whose fluorescence is controlled by the reaction of the substrate with 
the enzyme. The citrullination reaction leads to a change in the level of blue fluorescence, 
yielding a reliable read-out of PAD activity. This strategy has proven to be compatible 
with high-throughput screening platforms. The assay has several advantages over existing 
technologies, including a strong signal-to-noise ratio, speed of analysis, and robustness of 
measurement. Most importantly, it is technically facile and can be performed with readily 
available reagents.  Having shown that the assay is tolerant to a variety of conditions that 
are typically encountered in small molecule drug discovery efforts, we set out to employ 
it for high-throughput screening of potential PAD4 inhibitors. Working with the Drug 
Discovery Core Facility at Penn State Hershey Medical, we conducted a pilot screen of 
80 compounds in order to quantify the suitability of the assay for use in a high-
throughput screen. To measure suitability, a Z-factor or Z’ (Z-prime) is calculated based 
off of four parameters: the means and standard deviations of both the positive and 
negative controls.  
 
 
 
 
 
 
150 
 
 
 
 
 
 
 
 
 
 
In regarding the pilot screen, a robust Z’ value of 0.7 was identified making the 
assay very compatible for high-throughput robotics. To date, over 2,000 natural and 
FDA-approved compounds have been screened via our assay using the robotic lab at the 
Drug Discovery Core Facility. No positive hits have been discovered.    
 
 
 
 
 
 
 
 
 
 
 
1.0 Ideal Assay 
0.5 < X < 1.0 Excellent Assay 
0 < X < 0.5 Marginal Assay 
X < 0 
Too much overlap between 
positive and negative controls 
for the assay to be considered 
useful 
Table 5.1 Interpretation of Z-factor.  
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Chapter 6 
 
Materials and Methods 
 
6.1 Materials  
 
Protected amino acids were purchased from Chem-Impex. Fluorescein 5-
isothiocyanate and 5, 6-carboxyfluorescein were purchased from Chem-Impex. Amino-
PEG16-24-acid, DNP-PEG2-12-acid, and Fmoc-N-amido-PEG12-acid compounds were 
purchased from Broadpharm. Fmoc-8-amino-3,6-dioxaoctanoic acid was purchased from 
Chem Impex, International. Antibody was purchased from Vector Laboratories. Purified 
Human IgG, Normal Serum was purchased from Bethyl Laboratories. All other organic 
chemical reagents were purchased from Fisher Scientific or Sigma Aldrich and used 
without further purification. Dimethyl sulfoxide (DMSO) and Dulbecco’s modified 
Eagle’s medium (DMEM) were purchased from Thermo Fisher Scientific Inc. Fetal 
Bovine Serum (FBS) was purchased from Corning. Penicillin-Streptomycin was 
purchased from Sigma-Aldrich. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) was purchased from EMD Millipore.  
 
6.2 Mammalian Cell Culture  
Human embryonic kidney 293 cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% FBS, 100 U/mL penicillin, and 0.1 mg/mL 
streptomycin in a humidified atmosphere of 5% CO2 at 37 °C. 
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6.3 Bacterial Cell Culture  
Bacterial cells were cultured in specific media in an aerobic environment shaking at 250 rpm 
at 37 °C. S. aureus, S. epidermidis, B. subtilis, E. coli, Acinetobacter baumannii, Klebsiella 
pneumoniae, were all grown in Luria Bertani (LB) medium. P. aeruginosa were grown in 
Trypsin Soy Broth (TSB) medium. L. monocytogenes was grown in Brain Heart Infusion 
(BHI) medium. 
 
6.4 Bacterial Strains  
 Bacterial strains utilized in this work are as followed. 
Bacterial Strain Classification Chapter Reference 
B. subtilis NCIB 3610 Gram Positive 3 
S. aureus Newman  Gram Positive 3, 4 
S. aureus Sc01 Gram Positive 3 
S. epidermidis NRS101 Gram Positive 3 
L. monocytogenes 10403s Gram Positive 3 
E. coli MG1655 Gram Negative 3,4 
Acinetobacter baumannii 
ATCC 19606 
Gram Negative 4 
Klebsiella pneumoniae 
ATCC 13883 
Gram Negative 4 
Pseudomonas aeruginosa 
ATCC 27853 
Gram Negative 4 
Pseudomonas aeruginosa 
ATCC 27853 
Gram Negative 4 
E.coli XL1 Blue Gram Negative 5 
E. coli BL21 (DE3) Gram Negative  5 
 
 
6.5 Synthesis of FITC-conjugated anti-DNP Antibody 
 
     Anti-DNP rabbit (1 mg/mL) was suspended in 1 mL cold solution of 0.05 M boric 
acid, 0.2 M NaCl at a pH = 9.2 in a 30 KDa molecular weight cut-off centrifuge tube. 
Antibody was spun at 5,000g for 10 min at 4 °C (4X) to complete the wash process. A 
solution of 5 mg/mL of fluorescein 5-isothiocyanate (40 μL) was added to the washed 
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antibody solution (1mL). Solution rotated for 2 h protected from light. After reaction 
time, solution was washed in with 10 mM phosphate, 0.15 M NaCl, 0.08% NaN3 at pH = 
7.8, as before. Concentration was determined by absorbance at 280 nm and 480 nm via 
Shimadzu Biotech BioSpec-nano spectrophotometer.  
 
 
6.6 Solid Phase Peptide Synthesis of FITC-Conjugated Sortase Recognition Peptides 
 
A 25 ml synthetic vessel was charged with 564 g (0.41 mmol) of Rink Amide resin. 
The resin was initially deprotected in a solution of 6 M piperazine/100 mM HOBt in 
DMF (7 ml). The flask was agitated for 30 minutes and the deprotection solution was 
drained. The resin was washed with DMF, CH2Cl2, MeOH, CH2Cl2, and DMF (3 x 5 ml 
each). Initial loading of Fmoc-Gly (example for Sortase A peptide) (4 eq., 0.91 mmol), 
HCTU (3.9 eq., 0.88 mmol), and DIEA (8 eq., 1.80 mmol) in DMF (10 mL) was 
performed. The vessel was agitated for 2 h at room temperature. The resin was then 
washed with DMF, CH2Cl2, MeOH, CH2Cl2 and DMF (3 x 5 ml each). The Fmoc-
protecting group was removed with a solution of 6 M piperazine/100 mM HOBt in DMF 
(7 ml). The flask was agitated for 25 minute and the deprotection solution was drained. 
The resin was washed and the addition of the second amino acid was performed by 
adding Fmoc-protected amino acid (4 eq., 0.91 mmol), HCTU (3.9 eq., 0.88 mmol), and 
DIEA (8 eq., 1.80 mmol) in DMF (10 mL) and agitating for 2 hours. Peptide synthesis 
was continued for remaining Fmoc-protected amino acids and/or Fmoc-protected PEG 
groups. For the FITC modification addition, the resin was deprotected and 5, 6-
carbocyfluorescein (2 eq., 0.46 mmol), HCTU (1.9 eq., 0.44 mmol), and DIEA (4 eq., 
0.93 mmol) in DMF (10 mL) was added to the resin. The flask was agitated in the dark 
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overnight. The resin was drained and subsequently washed with DMF, CH2Cl2, MeOH, 
CH2Cl2 and DMF (3 x 5 ml each). The cleavage of the peptide from resin was carried out 
by addition of trifluoroacetic acid (TFA) cocktail solution (95% TFA, 2.5% TIPS, 2.5% 
H2O, 20 ml).  The mixture was agitated for 1 hour at room temperature. The resulting 
solution was concentrated via compressed air to remove the TFA. The residue was 
triturated in cold diethyl ether and the precipitate was collected by centrifugation and 
dissolved in H2O. Compounds were then purified using RP-HPLC with a Phenomenex 
C8 prep column and an eluent consisting of solvent A (H2O / 0.1% TFA) and solvent B 
(MeOH / 0.1% TFA) using a 60 minute gradient transitioning from 5% B to 100% B at a 
flow rate of 10 ml min-1. The purity of the peptides was verified by analytical reverse 
phase HPLC using a Phenomenex C18 column with an eluent consisting of solvent A 
(CH3CN/0.1% TFA) and solvent B (H2O/0.1% TFA) with a 30 minute gradient 
consisting of 5 to 100 % B, and a flow rate of 1 ml min-1 and monitored at 230 nm. 
Purified peptides were subsequently characterized using ESI-MS and MALDI-TOF MS.   
 
6.7 Solid Phase Peptide Synthesis of DNP-Conjugated Sortase Recognition Peptides 
 
The resin was initially deprotected in a solution of 6 M piperazine/100 mM HOBt 
in DMF (7 ml). The flask was agitated for 30 minutes and the deprotection solution was 
drained. The resin was washed with DMF, CH2Cl2, MeOH, CH2Cl2, and DMF (3 x 5 ml 
each). Initial loading of Fmoc-Gly (example for Sortase A peptide) (4 eq., 0.91 mmol), 
HCTU (3.9 eq., 0.88 mmol), and DIEA (8 eq., 1.80 mmol) in DMF (10 mL) was 
performed. The vessel was agitated for 2 h at room temperature. The resin was then 
washed with DMF, CH2Cl2, MeOH, CH2Cl2 and DMF (3 x 5 ml each). The Fmoc-
protecting group was removed with a solution of 6 M piperazine/100 mM HOBt in DMF 
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(10 ml). The flask was agitated for 25 minute and the deprotection solution was drained. 
The resin was washed and the addition of the second amino acid was performed by 
adding Fmoc-protected amino acids (4 eq., 0.91 mmol), HCTU (3.9 eq., 0.88 mmol), and 
DIEA (8 eq., 1.80 mmol) in DMF (10 mL) and agitating for 2 hours. Peptide synthesis 
was continued for remaining Fmoc-protected amino acids and/or Fmoc-protected PEG 
groups. For the DNP modification step, the resin was treated with 2, 4-
dinitrofluorobenzene (10 eq. 2.5 mmol) and DIEA (15 eq., 3.75 mmol) in DMF, and the 
flask was agitated in the dark for 1 hour at room temperature. The resin was drained and 
subsequently washed with DMF, CH2Cl2, and MeOH (3 x 5 mL each). The peptide was 
built with sequence, DNP-PEG-K(Mtt)LPMTG. The Nε-methyltrityl protecting group of 
the lysine was then deprotected by adding 10 mL of a TFA cocktail solution (1% TFA, 
2% TIPS in CH2Cl2) to the resin and agitating for 10 minutes protected from light. The 
solution was drained and this procedure was repeated four additional times. The solution 
was then drained and washed as previously stated. Upon MTT deprotection, Fmoc-8-
amino-3, 6-dioxaoctanoic acid (3 eq., 0.36 mmol), HCTU (0.36 eq., 0.36 mmol), and 
DIEA (6 eq., 0.72 mmol) in DMF was added to the resin. After 2 h of agitation, the resin 
was deprotected and washed as previously stated. Depending on the length of the PEG 
linker, additional PEG groups were added before cleaving the peptide from the resin. 
After 1 h agitation with TFA cocktail solution (95%, TFA, 2.5% TIPS, and 2.5 % H2O), 
the resin was concentrated to remove the TFA. The residue was triturated in cold diethyl 
ether and the precipitate was collected by centrifugation. Peptides were purified using 
RP-HPLC using a Phenomenex C8 prep column with an eluent consisting of solvent A 
(H2O / 0.1% TFA) and solvent B (MeOH / 0.1% TFA) using a 60 minute gradient 
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transitioning from 5% B to 100% B at a flow rate of 10 ml min-1. The purity of the 
peptides was verified by analytical RP-HPLC using a Phenomenex C4 column with an 
eluent consisting of solvent A (H2O /0.01% TFA) and solvent B (CH3CN / 0.01% TFA) 
with a 30 minute gradient transitioning from 5% B to 100% B at a flow rate of 3 ml min-
1 and monitored at 230 nm and molecular weight was confirmed using MALDI-TOF MS.  
 
6.8 Synthesis of Vancomycin-conjugated SrtA Recognition Peptides 
 
Vancomycin (20 mg, 0.0138 mmol) was dissolved in 1 mL 50/50 DMSO: DMF. 
Solution was cooled on ice and HCTU (5.13mg, 0.0124 mmol) and DIEA (7.2μL, 0.0414 
mmol) were added. SrtA recognition peptide, FITC(PEGm)K(PEGn)LPMTG or 
DNP(PEG2)K(PEG)LPMTG (1.5 eq.), was added to the mixture. Reaction continued on 
ice for 2 h with stirring. After time, mixture was filtered and injected into RP-HPLC for 
purification. Peptides were purified using RP-HPLC using a Phenomenex C8 prep 
column with an eluent consisting of solvent A (H2O / 0.001% TFA) and solvent B 
(MeOH / 0.001% TFA) using a 60 minute gradient transitioning from 5% B to 100% B at 
a flow rate of 10 ml min-1. The purity of the peptides was verified by analytical RP-
HPLC using a Phenomenex C4 column with an eluent consisting of solvent A (H2O 
/0.001% TFA) and solvent B (CH3CN / 0.001% TFA) with a 30 minute gradient 
transitioning from 5% B to 100% B at a flow rate of 3 ml min-1 and monitored at 230 nm 
and molecular weight was confirmed using MALDI-TOF MS.  
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6.9 Synthesis of PMBN-FITC 
 
Fluorescein isothiocyanate (FITC) (1.5 eq., 4.08 mg, 0.0105 mmol) was dissolved 
in DMF (100 μL). (BOC)PMBN (1eq., 10 mg, 0.007 mmol) was added to the fluorophore 
solution. DIEA (3eq., 3.65 μL, 0.021 mmol) was then added to the solution. Reaction 
progressed for 2 h while rotating protected from light. Reaction solution was purified on 
normal phase silica column with an eluent consisting of solvent A (CH2Cl2 / 0.01% 
DIEA) and solvent B (MeOH) with a 20 minute gradient transitioning from 0% B to 20% 
B at a flow rate of 18 ml min-1 and monitored at 280 nm and 254 nm. Product eluted at 
10% MeOH and molecular weight was confirmed using ESI-MS. Solvent was removed 
under reduced pressure and yellow oil was treated with acidic cocktail (50%, TFA, 2.5% 
TIPS, and 47.5 % CH2Cl2) for 2 h at room temperature to remove protecting groups. 
After reaction time, solvent was removed to yield 11 mg of PMBN-FITC. 
 
 
6.10 Synthesis of PMBN-PEGx-DNP 
 
Amino-PEG16-acid (Broadpharm 21880) (12.8 mg, 0.016 mmol) was dissolved 
in 200 μL of MeCN:0.1 M NaHCO3. 2, 4-dinitrofluorobenzene (1.5 eq, 3 μL) was added 
to the reaction and progressed for 2 h at room temperature protected from light. After 
reaction time, product was extracted in CH2Cl2: 2 M HCl and organic layer was isolated. 
Solvent was removed under reduced pressure and product was used without further 
purification. Synthesis repeated for DNP- PEG20-acid and PEG24-acid. DNP-PEG2-12-
acid compounds were purchased from Broadpharm.  
DNP-PEG16-acid (1.5 eq., 12 mg, 0.012 mmol) was dissolved in DMF (50 μL). 
HATU (1.4 eq., 4.7 mg, 0.0112 mmol) and DIEA (3 eq., 4.6 μL) were added to DNP-
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PEG16-acid solution. (BOC)PMBN (1 eq., 10.9 mg, 0.0079 mmol) was dissolved in 
DMF (100 μL). Solutions were mixed together and rotated for 2 h protected from light. 
After reaction time, product was resuspended in CH2Cl2:NaHCO3 and organic layer was 
isolated. Solvent was removed under reduced pressure. The resulting yellow oil was 
purified on normal phase silica column with an eluent consisting of solvent A (CH2Cl2 / 
0.01% DIEA) and solvent B (MeOH) with a 20 minute gradient transitioning from 0% B 
to 20% B at a flow rate of 18 ml min-1 and monitored at 280 nm and 254 nm. Product 
eluted at 19% MeOH and molecular weight was confirmed using MALDI-TOF MS. 
Solvent was removed under reduced pressure and yellow oil was treated with acidic 
cocktail (50%, TFA, 2.5% TIPS, and 47.5 % CH2Cl2) for 2 h at room temperature to 
remove protecting groups. After reaction time, solvent was removed to yield 13 mg of 
PMBN-PEG16-DNP. 
6.11 Synthesis of PMBN-PEGx-DNP(Oct) 
 
A 25 mL vessel was charged with 1 g (0.9 mmol) of 2-Chlorotrityl chloride resin. 
Initial loading with N-α-Fmoc-N-ε-4-methyltrityl-L-lysine (Fmoc-L-Lys(Mtt)-OH) (2 
eq., 1.8 mmol) and DIEA (4eq., 3.6 mmol) in anhydrous CH2Cl2 (10 mL) was performed. 
The vessel was agitated for 2 h at room temperature. The resin was washed with DMF, 
CH2Cl2, MeOH, CH2Cl2, and DMF (3 x 5 ml each). The N-terminus of lysine was 
deprotected in a solution of 6 M piperazine/100 mM HOBt in DMF (7 ml) for 30 min. 
Caprylic acid (5 eq.) was added to the vessel in DMF (10 mL) with HCTU (4.9 eq.) and 
DIEA (10 eq.). The vessel was agitated for 2 h at room temperature. The resin was 
washed as previously stated. Selective unmasking of the Nε-methyltrityl protecting group 
was completed in mild acidic conditions of 2 % TFA in CH2Cl2. Fmoc-N-amido-PEG12-
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acid (2 eq.) was added to the resin in DMF (10 mL) with HCTU (1.9 eq.) and DIEA (4 
eq.). After shaking for 4 h, the resin was washed and deprotected, as previously stated. 2, 
4-dinitrofluorobenzene (8 eq.) was added to the reaction and progressed for 3 h at room 
temperature protected from light. After reaction time, resin was again washed and 
cleaved from resin in acidic conditions. After removing solvent, product was isolated and 
used without further purification. Lys(PEG12)-DNP(Oct) was conjugated to (BOC)PMBN 
following reaction steps as mentioned in 6.10. 
 
6.12 SrtA Mediated Fluorescent Labeling 
 
Bacteria were grown in presence of FITC-labeled SrtA recognition peptides or 
FITC-labeled vancomycin-conjugated SrtA recognition peptides (5 μM) overnight at 37 
°C with shaking at 250 rpm in LB media. The next morning, the bacteria were harvested, 
washed 3X in 1X phosphate buffered saline (PBS), and fixated with 2% formaldehyde 
solution and analyzed via flow cytometry on a BDFacs Canto II flow cytometer (BD 
Biosciences, San Jose, CA) equipped with a 488 nm argon laser and a 530 bandpass filter 
(FL1). A minimum of 10,000 events were counted for each data point. The data were 
analyzed using the FACSDiva version 6.1.1 software. Cells were also imaged with 
fluorescent confocal microscopy.  
 
6.13 Antibody Binding Assay in S. aureus (Wood Strain) 
 
S. aureus (Wood Strain) bacteria were grown at 37 °C overnight in LB broth, 
supplemented with 0.4 µg mL-1 tunicamycin and DNP-2PEG1Vanc at designated 
concentrations with shaking at 250 rpm. The bacteria were harvested and washed 3X with 
1X phosphate buffer saline (PBS).  Approximately 2 × 106 colony forming units (CFU) 
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were then incubated in 100 µL of PBS containing 10% (v/v) FBS and 0.02 µg / mL of 
FITC-conjugated rabbit anti-dinitrophenyl IgG. All experiments were protected from 
light and incubated at 37 °C for 1 hour. Samples were then immediately analyzed by flow 
cytometry. Fluorescence data are expressed as mean arbitrary fluorescence units and were 
gated to include all healthy bacteria.  
 
6.14 Antibody Binding Assay in S. aureus 
 
S. aureus bacteria were grown at 37 °C overnight in LB broth, supplemented with 
0.4 µg mL-1 tunicamycin and DNP-2PEG1Vanc (5 μM) with shaking at 250 rpm. The 
bacteria were harvested and washed 3X with 1X phosphate buffer saline (PBS).  
Polyclonal antibody (0.02 μg / mL) was added to bacteria for 20 min at 4 °C. Cells were 
washed and roughly 2 × 106 colony forming units (CFU) were then incubated in 100 µL 
of PBS containing 10% (v/v) FBS and 0.02 µg / mL of FITC-conjugated rabbit anti-
dinitrophenyl IgG. All experiments were protected from light and incubated at 4 °C for 
30 min. Cells were washed 1X PBS and fixated in 2 % formaldehyde. Samples were then 
analyzed by flow cytometry. Fluorescence data are expressed as mean arbitrary 
fluorescence units and were gated to include all healthy bacteria.  
 
6.15 Bacterial Labeling in live C. elegans 
 
N2 Caenorhabditis elegans were maintained by standard protocol using nematode 
growth agar with bacterial lawns of E.coli OP50 (source) on a 60mm x 15mm cell culture 
dish. For bacterial labeling assays, C. elegans were grown to contain primarily L4 larval 
stage nematodes by incubation at 25 °C for ~48-52 h. On the day of experiments, C. 
elegans were washed off the plates with M9 buffer, and washed three times with M9 
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buffer. For washing steps, the C. elegans were pelleted at 1000g. The C. elegans were 
resuspended in 450 μL of M9 buffer containing 10% LB broth and transferred to a sterile 
24 multiwell plate. For infection, Staphylococcus aureus Sc01 of an overnight growth 
was harvested at 6000g and washed three times with original culture volume of M9 
buffer. The bacteria were resuspended in original culture volume in M9 buffer containing 
10% LB broth and 50 μL of the bacterial cells were added to the 450 μL suspension of C. 
elegans. The C. elegans were incubated at 25 °C for 4 h, harvested at 1000g and washed 
three times with M9 buffer to remove excess bacteria in the extracellular space. The C. 
elegans were then resuspended in 500 μL of M9 buffer containing 10% LB broth and 50 
μM FITC(PEG2)K(PEG-Vanc)LPMTG (FITC-2PEG1Vanc).  C. elegans were incubated 
for an additional 30 min at 25 °C. The C. elegans were harvested at 1000g, and washed 
three times with M9 buffer, and put into a final suspension of 10 mM sodium azide in M9 
buffer and analyzed by confocal microscopy. 
(Source) Lewis, J. A. & Fleming, J. T. (1995) Caenorhabditis elegans: Modern Biological 
Analysis of an Organism, eds. Epstein, H. F. & Shakes, D. C. (Academic, San Diego), Vol. 48, 
pp. 3–29. 
 
 
6.16 Minimal Inhibitory Concentration Assay 
 
The MICs of conjugates were determined by broth microdilution. Experiments 
were performed with Cation-adjusted Mueller-Hinton Broth (CaMHB) in 96-well 
polypropylene microtiter plates. Wells were inoculated with 200 μL of bacterial 
suspension prepared in CaMHB (containing ∼106 colony forming units (CFU) / mL) and 
200 μL of CaMHB containing increasing concentrations of the conjugates (0 to 100 
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µg/mL). The MIC was defined as the lowest concentration at which visible growth was 
inhibited following 18 h incubation at 37 °C. 
 
6.17 Mammalian Cell Viability Assay 
 
HEK293 cells were seeded in 96-well plates at a density of 10, 000 cells/well and 
incubated overnight. Prior to treatment, constructs were dissolved in DMSO to obtain 
desired aliquoted stock solutions. Appropriate volumes of these stock solutions were 
added to DMEM media so the final concentration of DMSO was equal to 1%.  After 
removal of cell media, 200 µL of treatment solutions were added to each well and 
incubated at 37 °C for 72 h. After treatment, the media was removed and the cells were 
washed with 100 µL of complete DMEM. Next, 100 µL of complete DMEM was added 
to each well. Cell viability was determined using the colorimetric 3-(4,5-dimethylthiazol-
2yl)-2,5 diphenyltetrazolium bromide (MTT) assay, in which 10 μL of a 5 mg/mL MTT 
stock solution was added to the treated cells and incubated for 2 h at 37 °C. The resulting 
formazan crystals were solubilized in 200 μL of DMSO. Absorbance was measured at 
580 nm using an Infinite 200 PRO microplate reader (Tecan). Cell viability was 
calculated against control cells treated with complete medium. 
 
6.18 Fluorescent Imaging 
 
Medium containing fluorescent conjugate was prepared to desired concentration. 
Bacteria were inoculated (1:100) in the corresponding medium and allowed to grow at 
designated time points or overnight at 37 °C. The bacteria were harvested at 1,000g and 
washed with 1X PBS (3X). The bacteria were analyzed on a glass slide by fluorescent 
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confocal microscopy using a B-2E/C filter (ex 465-495/em 515-555) for bacteria labeled 
with FITC fluorophore.  
 
6.19 PMBN-FITC E. coli Labeling 
 
E. coli were grown overnight in LB media. Concentrated (0 - 40 μM) aliquots of 
PMN-FITC were prepared in LB. Stationary phase E. coli (OD600 = 1.4) were harvested, 
suspended in PMN-FITC concentrated media, and shaken at 250 rpm for designated time 
points at 37 °C.  After treatment, bacteria were harvested, washed with 1X phosphate 
buffered saline (PBS) 3X, and fixated with 2% formaldehyde solution and analyzed via 
flow cytometry on a BDFacs Canto II flow cytometer (BD Biosciences, San Jose, CA) 
equipped with a 488 nm argon laser and a 530 bandpass filter (FL1). A minimum of 
10,000 events were counted for each data point. The data were analyzed using the 
FACSDiva version 6.1.1 software. Cells were also imaged with fluorescent confocal 
microscopy.  
 
6.20 Dissociation of PMBN-FITC from E. coli Surface 
 
Stationary phase E. coli (2 mL) were treated with 40 μM PMN-FITC for 2 h in 
LB media at 37 °C. After treatment, 2 mL of cells were harvested, washed with 1X PBS, 
and resuspended in 2 mL of PBS. Cells were shaken at 250 rpm at 37 °C. At designated 
time points, 0 – 24 h, 100 μL of cells were harvested, washed and fixated with 2% 
formaldehyde solution.  All fixed samples were analyzed via flow cytometry as 
previously stated.  
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6.21 PMBN-PEGx-DNP Antibody Binding Assay 
 
Stationary phase bacteria (600 μL) were treated with 40 μM PMN-PEGx-DNP for 
2 h in media at 37 °C. After treatment, cells were harvested and washed with PBS 3X. 2 
× 106 colony forming units (CFU) were then incubated in 100 µL of PBS containing 10% 
(v/v) FBS and 0.02 µg / mL of FITC-conjugated rabbit anti-dinitrophenyl IgG. All 
experiments were protected from light and incubated at 37 °C for 1 h. Cells were washed 
1X PBS and fixated in 4 % formaldehyde. Samples were then analyzed by flow 
cytometry. Fluorescence data are expressed as mean arbitrary fluorescence units and were 
gated to include all healthy bacteria.  
  
6.22 Bacterial Opsonization with Pooled Human Serum 
E. coli MG1655 was grown at 37 °C in LB broth with shaking. Stationary phase 
E. coli (OD = 1.4) were incubated with 40 µM of PMN-PEG12-DNP or PMN-PEG12-
DNP-octanoic acid for 15 min, 30 min or 60 min. The bacteria were harvested and 
washed 3X with PBS solution, and fixated in 4 % formaldehyde. Bacteria were then 
washed 2X with LB media. Pooled human serum was diluted to 25% in PBS solution 
with 10 % FBS and incubated with bacteria at 4 °C for 20 min. The opsonized bacteria 
were then washed with PBS and 2 × 106 colony forming units (CFU) were incubated with 
Anti-Human IgG-FITC diluted 1:1000 in PBS containing 10% FBS at 4 °C for 30 min 
protected from light. Cells were washed 1X PBS and fixated in 4 % formaldehyde. 
Samples were then analyzed by flow cytometry as previously stated.  
 
 
168 
 
6.23 Time-kill Studies of Stationary-phase E. coli 
High cell density stationary-phase cultures of E. coli in MH broth were treated 
with various concentrations of PMBN-PEG12-DNP (0, 17.3, 34.6, 69.2, 103.7, 138.3, 
172.9 μg /mL or 10, 20, 40, 60, 80, 100 µM). Time-kill studies were performed at 37 °C 
with shaking at 250 rpm. Culture aliquots (10 μL) were removed at the times shown in 
the figures, serially diluted in 1X PBS (pH 7.4 to 7.6), and then plated on LB agar and 
incubated overnight in a 37 °C incubator. Cell viability was assessed by enumerating the 
CFU per milliliter. Bactericidal activity was defined as a log reduction with antibiotic 
treatment compared with the untreated control at the start of each assay.  
 
6.24 Antibiotic Potentiation Assay 
 Antibiotic synergy was determined by broth microdilution assays. Experiments 
were performed with cation-adjusted Mueller-Hinton Broth (CaMHB) in 96-well 
polypropylene microtiter plates. Wells were inoculated with 200 μL of bacterial 
suspension prepared in CaMHB (containing ∼106 colony forming units (CFU) / mL) and 
200 μL of CaMHB containing increasing concentrations of the antibiotics (0 to 100 
µg/mL) and 25 μg / mL of PMBN-PEG12-DNP. The MIC was defined as the lowest 
concentration at which visible growth was inhibited following 18 h incubation at 37 °C. 
Data are representative of at least three biological replicates. Fractional inhibitory 
concentration (FIC) indices were calculated according to: 
FIC index = (MICac / MICa)  +  (MICbc / MICb) = FICa  +  FICb 
where MICa is the minimum inhibitory concentration (MIC) of compound A alone; 
MICac is the MIC of compound A in combination with compound B; MICb is the MIC of 
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compound B alone; MICbc is the MIC of compound B in combination with compound A; 
FICa is the FIC of compound A; FICb is the FIC of compound B. Synergy is defined as an 
FIC index of ≤0.5. Antagonism is defined as an FIC index of ≥4. 
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Appendices 
 
A.1 Molecular Weights and Purities of FITC-Conjugated SrtA Recognition Peptides 
 
 
 
 
 
 
 
 
 
 
 
Compound 
Calculated        
[M + H+]
Found         
[M + H+]
Purity
FITC-KLPETG 1003.43 1003.046 >95%
FITC-KLPMTG 1005.43 1005.337 >95%
FITC(PEG)K(PEG)LPMTG 1295.58 1295.159 >95%
FITC(PEG)K(PEG2)LPMTG 1440.65 1439.911 >95%
FITC(PEG)K(PEG3)LPMTG 1585.73 1585.035 >95%
FITC(PEG2)K(PEG)LPMTG 1440.65 1440.24 >95%
Compound 
Calculated        
[M + Na+]
Found         
[M + Na+]
Purity
FITC-KMGTLP 1027.42 1027.139 >95%
FITC(PEG)KLPMTG 1172.5 1172.911 >95%
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Analytical RP-HPLC Profiles of FITC-conjugated SrtA Recognition Peptides: The 
specified derivatives were analyzed on a Phenomenex C4 column by reverse phase HPLC 
with an eluent consisting of solvent A (H2O /0.1% TFA) and solvent B (CH3CN /0.1% 
TFA) with a 30 minute gradient consisting of 5 to 100 % B, a flow rate of 3 mL/min, and 
monitoring at 230 nm. 
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A.2 Molecular Weights and Purities of Vancomycin-Conjugated SrtA Recognition 
Peptides 
 
 
 
 
 
 
 
 
 
 
 
 
Compound 
Calculated        
[M + H+]
Found         
[M + H+]
Purity
FITC(PEG)-K(Vanc)LPMTG 2582.54 2582.163 >95%
Compound 
Calculated        
[M + K+]
Found         
[M + K+]
Purity
FITC(PEG)-K(PEGVanc)LPMTG 2765.78 2765.241 >95%
FITC(PEG)-K(PEG3Vanc)LPMTG 3057.01 3057.809 >95%
Compound 
Calculated        
[M + Na+]
Found         
[M + Na+]
Purity
FITC(PEG)-K(PEG2Vanc)LPMTG 2894.84 2894.55 >95%
FITC(PEG2)K(PEGVanc)LPMTG 2894.84 2894.622 >95%
DNP(PEG2)K(PEGVanc)LPMTG 2700.62 2700.454 >95%
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Analytical RP-HPLC Profiles of FITC(PEG)K(PEGNVanc)LPMTG-NH2  Peptides : 
The specified derivatives were analyzed on a Phenomenex C4 column by reverse phase 
HPLC with an eluent consisting of solvent A (H2O /0.001% TFA) and solvent B 
(CH3CN /0.001% TFA) with a 30 minute gradient consisting of 5 to 100 % B, a flow rate 
of 3 mL/min, and monitoring at 230 nm. 
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Analytical RP-HPLC Profile of DNP(PEG2)K(PEGVanc)LPMTG-NH2 : The 
specified derivative was analyzed on a Phenomenex C18 column by reverse phase HPLC 
with an eluent consisting of solvent A (H2O /0.001% TFA) and solvent B (CH3CN 
/0.001% TFA) with a 30 minute gradient consisting of 5 to 100 % B, a flow rate of 1 
mL/min, and monitoring at 230 nm. 
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A.3 Molecular Weights and Purities of FITC-Conjugated SrtB Recognition Peptides 
 
 
Analytical RP-HPLC Profiles of FITC-conjugated Sortase B Peptide: The specified 
peptide was analyzed on a Phenomenex C18 column by reverse phase HPLC with an 
eluent consisting of solvent A (H2O /0.1% TFA) and solvent B (CH3CN /0.1% TFA) 
with a 30 minute gradient consisting of 5 to 100 % B, a flow rate of 1 mL/min, and 
monitoring at 230 nm. 
 
 
 
 
 
 
Compound 
Calculated        
[M + H+]
Found         
[M + H+]
Purity
FITC(PEG)-NAKTN 1052.06 1052.136 >95%
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A.4 Molecular Weights and Purities of PMBN Conjugates  
 
 
 
 
 
 
 
 
 
 
Compound 
Calculated        
[M + Na+]
Found         
[M + Na+]
Purity
PMBN-PEG2-DNP 1311.399 1311.815 >98%
PMBN-PEG4-DNP 1399.499 1399.842 >98%
PMBN-PEG6-DNP 1487.609 1487.829 >98%
PMBN-PEG12-DNP 1751.919 1751.447 >98%
PMBN-PEG16-DNP 1928.123 1928.094 >98%
PMBN-PEG20-DNP 2104.349 2104.221 >98%
PMBN-PEG24-DNP 2280.559 2279.925 >98%
Compound 
Calculated        
[M + H+]
Found         
[M + H+]
Purity
PMBN-FITC 1353.52 1354.304 >98%
PMBN-PEG12-DNP(Oct) 1983.2 1983.476 >95%
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